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Chapter 1 - Thesis topic and outline 
This thesis describes the use and development of innovative tools, both radiological and bioengineering, in 
supporting clinical diagnosis of chronic obstructive pulmonary disease (COPD). Radiology was coupled with 
pulmonary function to better understand this complex and heterogeneous disease and to describe its phenotypes 
and endotypes. An overview of the clinical and radiological complexity of COPD and the current role of 
imaging is presented in the first part (Chapters 1 and 2). The second part (Chapters 3 to 7) focuses on statistical 
and mathematical models that classify patients for having the emphysematous phenotype based uniquely on 
clinical and functional data. Innovative imaging techniques have been tested and used as gold standards. The 
third part (Chapter 8 and 9) examines the ongoing questions and future directions of research in the field.  
Part I 
Chapter 1   COPD: a complex and heterogeneous disease  
Chapter 2   Radiology and Radiomics 
Part II 
Chapter 3   Emphysematous and nonemphysematous gas trapping in COPD 
Chapter 4   Statistical models: lung function and BMI 
Chapter 5   Statistical models: maximal expiratory flow-volume curve 
Chapter 6   Mathematical model and radiomics 
Chapter 7   Validation ESI model 
Part III 
Chapter 8   Which criteria to define COPD? 
Chapter 9   Future directions 
Chapter 10  Conclusions 
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Chapter 2 - COPD: a complex and heterogeneous disease 
Chronic obstructive pulmonary disease (COPD) is characterized by expiratory airflow limitation caused 
by increased resistance of the small airways and/or increased compliance of the lung as a result of emphysema. 
The volume of air that can be expired within 1 s after the beginning of a forced expiration (FEV1) is the 
hallmark of COPD, as expiratory airflow is affected by inflammation and remodeling of the small airways as 
well as by emphysematous destruction of lung parenchyma. Spirometric detection of not fully reversible 
airflow limitation unifies under the acronym COPD a spectrum of heterogeneous conditions, different from 
the clinical, functional, and pathological perspective. 
Fifty years ago Burrows described the distinctive clinical, functional, radiological, and pathological 
characteristics that differentiate those patients with COPD during life who presented with parenchymal 
destruction or involvement of the small airways at autopsy (1). The terms type A (pink puffer) and type B 
(blue bloater) introduced to empirically differentiate COPD patients with the emphysematous type from those 
with the small airway disease type of chronic airways obstruction are no longer in use because a direct 
association between clinically defined phenotypes and lung pathologic findings, such as centrilobular and 
panlobular emphysema, has never been demonstrated (2). The observation that the pathological findings of 
small airways disease and parenchymal destruction often coexist in the same patient has substantially 
contributed to the introduction and wide use of the term “COPD” for the whole population of patients with 
chronic irreversible airflow limitation. However, spirometric parameters, such as FEV1 and forced vital 
capacity (FVC), cannot provide a panoramic view of the complexity and heterogeneity of COPD. Different 
types of emphysema may coexist in the same patient and the mechanical properties of the lung differ according 
to the predominant type.  
In 2009 Ogawa et al. elegantly brought back to life and strengthened Burrows’ findings of the sixties by 
using high resolution computed tomography (CT) (3). They found that patients with COPD who had low 
attenuation areas (compatible with emphysematous destruction of lung parenchyma) were thinner than those 
who had bronchial wall thickening (compatible with chronic inflammatory changes of the small airways). A 
significant inverse relationship was found between body mass index (BMI) and emphysema extent at CT, 
whereas there was no correlation between BMI and thickness of the bronchial wall. FEV1 inversely correlated 
with BMI, CT emphysema extent and bronchial wall thickness, but there was no significant difference in FEV1 
between the two CT phenotypes of COPD (3). These findings suggest that patients with COPD may have 
different systemic clinical manifestations (phenotypes), reflecting different pathophysiological mechanisms 
(endotypes) of expiratory airflow limitation (4). Moreover, the various endotypes may respond differently to 
therapy, which could possibly explain the deceiving results of some pharmacological trials (8). 
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From: Woodruff P et al. The Lancet 2015 385, 1789-98. 
Endotypes can be characterized in vivo by using CT. Together with the emphysema extent, airway wall 
thickness on CT has been used to help classifying patients with expiratory airflow limitation as having either 
a predominant emphysema phenotype (increased lung compliance) or a predominant small airway disease 
phenotype (increased airway resistance) (5-7). The recent technological advances in imaging acquisition and 
post-processing of image data have brought to advances into the understanding of such a complex and 
heterogeneous disease as COPD. 
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Chapter 3 - Radiology and Radiomics 
Chest radiography has been used for many years to evaluate the entire chest in COPD patients. However, 
the advent of CT and the recent advances in acquisition as well as in post-processing of image data have lead 
to a significant improvement in the in vivo characterization of COPD. 
CT is the most widely available and precise imaging method for the characterization of COPD. CT is a 
well-validated technique to assess qualitatively and quantitatively the presence, pattern, and extent of 
emphysema (1, 2). Quantification of low-attenuation areas, expiratory gas trapping, and airway wall thickness 
can help define specific COPD subtypes with different clinical and physiologic features (3). 
The Fleischner Society in 2015 released a Statement on CT-definable subtypes of COPD that included a 
wide spectrum of emphysema and airway disease subtypes (4). The criteria to classify the subtypes rely on 
both quantitative and qualitative parameters.  
Qualitative analysis defines the presence and subtype of emphysema, airway wall thickening, and the 
features associated, such as tracheobronchomalacia, bronchiectases, coexistence of interstitial lung disease, 
pulmonary hypertension, morphology of chest wall and large airways (4). Semiquantitative scores to quantify 
pulmonary emphysema have been used, but quantitative analysis overtakes radiologists performance (5).  
Quantitative analysis can be performed nowadays by using many different software programs, either free 
or commercially available. Most of them execute a densitometric analysis of lung parenchyma and the 
segmentation of airways and lobes, providing parameters of low attenuation areas, airway wall thickening, and 
airway luminal area. More advanced programs can also provide parameters on pulmonary vasculature (i.e. 
vessel volume, vessel caliber, distinction between arteries and veins). Nowadays these software programs are 
fully automated and some of them allow the manual correction if any mistake occur. The time needed to 
perform these analyses vary according to the program used, ranging from 5 to 10 minutes per CT scan.  
Inspiratory CT scan is performed at total lung capacity, whereas expiratory scan can be performed either 
at forced vital capacity or at residual volume. Spirometric gating allows scanning the chest at predefined lung 
volumes to avoid the influence of the level of lung inflation during scanning on CT attenuation measurements 
(6, 7). However, the level of lung inflation is not the only parameter affecting the assessment of the disease at 
CT. Quantitative analysis can also be affected by a large number of factors, such as variability in technical 
parameters of acquisition (slice thickness, convolution kernels, iterative reconstructions, kVp and mAs), 
calibration of CT scanners, CT vendors, patient’s BMI, presence of motion or hard-beam artifacts, coexistence 
of other lesions, and post-processing image analysis (8). Recently a new factor has been added to this long list: 
the elastic deformation of paired inspiratory and expiratory scans performed at coregistration analysis. 
Coregistration analysis provides the relative volume of functional gas trapping, namely the gas trapped in 
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expiration not due to emphysema (9, 10). This deformation creates parametric response maps where each voxel 
has an attenuation value different from both the native paired CT scans. 
The exponential growth in medical image analysis has brought to an increased number of pattern 
recognition tools and the increase in data set sizes. These advances have facilitated the development of 
processes for high-throughput extraction of quantitative features that result in the conversion of images into 
mineable data and the subsequent analysis of these data for decision support. This practice is termed radiomics. 
Radiomics allows the simultaneous use of a large amount of parameters extracted from imaging data. These 
parameters are mathematically processed with advanced statistical methodologies (11). Radiomic data contain 
first-, second-, and higher-order statistics (12). These data are combined with other patient data and are mined 
with sophisticated bioinformatics tools to develop models that may potentially improve diagnostic, prognostic, 
and predictive accuracy (13). 
 
 
From: Gillies R et al. Radiology 2016; 278:563–77 
 
The novelty of the methodology carries many difficulties nowadays, especially in the choice of which 
parameters to extract from the images. Each tool calculates a different number of features, belonging to 
different categories, and the initial choice may appear somehow arbitrary. Nonetheless, the methodologies for 
data analysis strictly depend on the number of input variables, possibly affecting the final result. One approach 
is to start from all the features provided by the calculation tool and to perform a preliminary analysis to select 
the repeatable and reproducible parameters, to subsequently reduce them by correlation and redundancy 
analysis. Another approach is to make an a priori selection of the features, based on their mathematical 
definition, focusing on the parameters easily interpretable in terms of visual appearance, or directly 
connectable to some biological properties of the tissue. Alternatively, machine-learning techniques, underlying 
the idea that computers may learn from past examples and detect hard-to-discern patterns from large and 
complex datasets, are used and emerging today as a useful tool to select appropriate features (14, 15).  
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Although radiomics features can be calculated by dedicated software programs, which are user-friendly 
and timely wise, it is still mandatory to carefully check the quality of the input data and to select the optimal 
parameters to guarantee reliable and robust output (16). The huge amount of information provided by this new 
methodology should be accurately evaluated and its clinical meaning explored. 
Advances in technical equipment allowed the generation of microCT scans. The analysis of lung 
parenchyma at a 16.24μm isotropic voxel resolution allows visualizing the terminal bronchioles to the point at 
which they branched into respiratory bronchioles (17). An estimate of the total number of terminal bronchioles 
as well as the total cross-sectional area of all terminal bronchioles per lung can be obtained, providing useful 
information in the assessment of COPD subtypes. However, microCT can assess only frozen lung specimens, 
making microCT fully dedicated to research. 
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Chapter 4 - Emphysematous and nonemphysematous gas 
trapping in chronic obstructive pulmonary 
disease 
 
Emphysematous and nonemphysematous gas trapping in Chronic Obstructive Pulmonary 
Disease: Quantitative CT Findings and Pulmonary Function 
Mariaelena Occhipinti, Matteo Paoletti, Francesca Bigazzi, Gianna Camiciottoli, Riccardo Inchingolo,  
Anna R. Larici, Massimo Pistolesi 
Radiology 2018; 287:683–692 
 
4.1 Introduction 
The wide heterogeneity of clinical presentation makes chronic obstructive pulmonary disease (COPD) a 
complex disease, which deserves deeper insights beyond airflow obstruction detected at spirometry. The 
advent of computed tomography (CT) has brought in the last twenty years substantial progress in the 
assessment of the pathophysiologic mechanisms underlying airflow obstruction in COPD, namely emphysema 
and conductive airway disease (1). However, the possibility to accurately resolve by CT the relative 
contribution of emphysematous and non-emphysematous gas trapping in the determination of expiratory 
airflow obstruction is still matter of study, to our knowledge (2). Recently, Galban et al. proposed an innovative 
method called pulmonary parametric response map (pPRM), based on the co-registration of paired inspiratory 
and expiratory thoracic CT scans. This method can dissect and display the regional distribution of the persistent 
low density area (emphysematous gas trapping, due to parenchymal destruction), and the functional low 
density area (non-emphysematous or functional gas trapping due to conductive airway disease) (3). 
Although in an individual patient one of the two pathophysiologic conditions (endotypes) may prevail, most 
COPD patients present (phenotype) with a mixed disorder characterized by various combinations of both 
components, and a corresponding mixed CT subtype (4, 5). Knowledge of the prevalent subtype in each patient 
may be of interest in developing clinical and pharmacological trials designed to target patient therapy to the 
underlying pathophysiologic mechanism of airflow obstruction. Conductive airway obstruction and 
parenchymal destruction may not be targetable with the same therapy. Therefore, we aimed at identifying a 
prevalent CT subtype, by dissecting each contribution to total gas trapping. We also evaluated the prediction 
and grading by clinical and functional data the contribution of emphysema to total gas trapping as assessed 
using non-contrast thin-section thoracic CT. 
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4.2 Materials and Methods 
This two center study was approved by both institutional Ethics Committees of the University of Florence 
and the Catholic University of Sacred Heart in Rome. Written informed consent was obtained by all 
participants. M.O. reports consultancies from Imbio, LLC (Minnesota, MN) and a grant financed partly from 
MENARINI and partly from the University of Florence, during the conduct of the study. M.Pistolesi reports 
grants from Ministry of Health of Italy as well as from Ministry of University and Research of Italy, during 
the conduct of the study. The authors had control of the data and of the information submitted for publication. 
Our study was based on a retrospective interpretation of prospectively acquired data. From January 2012 
to December 2015, we recruited 224 consecutive eligible COPD patients (GOLD stages I-IV) meeting specific 
criteria, including being aged 40–85, with a smoking history of more than 10 pack-years, who showed non-
reversible post-bronchodilator airflow obstruction, and who underwent chest CT within 48 hours of pulmonary 
function evaluation. We excluded patients within one month of an exacerbation or who had clinical conditions 
interfering with pulmonary function or chest CT quantitative parameters assessment, including asthma, diffuse 
bronchiectasis, interstitial lung disease, acute heart failure, chemotherapy and/or radiation therapy, lung 
cancer, lung surgery, and metal objects in the chest. 
4.2.1 Pulmonary Function Testing 
All patients underwent complete pulmonary function evaluation within 48 hours of the CT examination. 
Pre-and post-bronchodilator spirometry data, static lung volumes, and single-breath diffusing capacity for 
carbon monoxide (DLco) were measured according to American Thoracic Society/European Respiratory 
Society (ATS/ERS) guidelines (6). 
4.2.2 Chest CT Scan 
Volumetric chest CT scans were obtained at full inspiration and expiration using the acquisition protocol 
adopted in the COPDGene study (7). CT parameters were set as follows: 120 kVp, 200 mAs, rotation time 
0.5s, pitch 1.1, slice thickness 0.75mm, and reconstructions kernels b31f and b70f. All CT scans were 
performed by the same team of diagnostic personnel in each center (lead by F.B. in Florence and A.R.L. in 
Rome, with 10 and 20 years of expertise in thoracic imaging, respectively) and by using the same CT scanner 
for all patients in each center (in Florence: SOMATOM Sensation 64, Siemens, Erlangen, Germany; in Rome: 
SOMATOM Definition FLASH 128, Siemens, Erlangen, Germany). Patients received prior careful 
instructions on how to perform the respiratory maneuvers while lying supine in the CT scanner with arms fully 
abducted. No contrast medium was administered. Post-processing image analysis was performed in images 
with reconstruction kernel b31f by a thoracic radiologist with 5 years expertise on quantitative imaging (M.O.). 
Thresholds at -950 Hounsfield Units (HU) and -856 HU were chosen as densitometric cut-off consistent with 
emphysema and total gas trapping, respectively (8-10). The relative volumes of lung attenuation area with 
values below -950 HU at inspiration (%LAA-950insp) and below -856 HU at expiration (%LAA-856exp) were 
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quantified by using the Pulmonary Workstation Apollo 2.1 (VIDA Diagnostics, Coralville, Iowa, USA). CT 
scans were also analyzed by LDA (Imbio LLC, Minneapolis, MN, USA), a U.S. FDA-cleared and CE 
(Conformité Européenne) mark certified medical device, which performs a deformable co-registration of 
paired inspiratory and expiratory CT scans, to obtain voxel-by-voxel attenuation maps. These maps, called 
pPRM, classify lung voxels into three different tissue patterns based on the attenuation values of each voxel: 
normal lung (% voxels with CT attenuation above -950HU at inspiration and above -856HU at expiration), 
functional low density area (%fLDA, voxels with CT attenuation above -950HU at inspiration and below -
856HU at expiration), and persistent low density area (%pLDA, voxels with CT attenuation below -950HU at 
inspiration and below -856HU at expiration) (3). Moreover, pPRM quantify the relative volumes of each lung 
pattern and show their regional distribution.  
4.2.3 Data analysis 
Scatterplots were used to show the distribution and the relationships among CT parameters. Pearson r 
coefficient was used to assess association between parameters, with p <0.05 indicating statistical significance.  
To quantify the contribute of functional gas trapping to the CT reduced x-ray attenuation using CT density 
thresholds without co-registration, we used the following computation:  
%fGT = [%LAA-856exp − (%LAA-950insp − 6%)] 
where 6% of voxels below -950HU is assumed as the threshold value to diagnose emphysema by 
quantitative CT (1). To validate this computation we compared %fGT with %fLDA.  
To help separating the contribution of functional gas trapping from emphysema, the scatterplot of %fGT 
and %LAA-950insp of the whole series of patients was subdivided into four areas by drawing a line from the 
mean value of %fGT on the x-axis (36.2%) and its perpendicular from the mean value of %LAA-950insp on the 
y-axis (14.9%). Welch's t, ANOVA, and Games-Howell post-hoc test were used to evaluate differences of 
clinical and functional data between the four groups of patients entailed in each area (11).  
The probability to have a %LAA-950insp above or below the sample mean was estimated by a ten-fold 
validated logistic regression model built from stepwise selection of anthropometric, clinical, and functional 
data (see online Supplemental Material for detail) (12). A predicted probability (P) value of 0.5 was arbitrarily 
selected as decision threshold. For the sake of clinical classification, patients with a P value lower than 0.5 
were subdivided in two subgroups according to a P value lower or higher than 0.2. Likewise, patients with a P 
value higher than 0.5 were subdivided in those with a P value higher or lower than 0.8. 
Data analysis and statistics were performed using S-Plus 2000 (Mathsoft, Cambridge, MA), SPSS/PC WIN 
11.5.1 (SPSS, Chicago, IL), Mathcad (version 2001; Mathsoft), and C++ programming language. 
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4.3 Results 
Two hundred and two (159 men, mean age 71, age range: 41-85; 43 women, mean age: 67, age range: 46-
84) out of the 224 patients enrolled were included in the analysis. Twenty-two patients were excluded for the 
presence of parenchymal consolidations (16/22) or incomplete clinical (4/22) or CT scan (2/22) data. 
Anthropometric, smoking history, lung function, and CT metrics data of the 202 patients are shown in Table 
1.  
Table 2 shows the correlations between clinical, pulmonary function, and CT data. The strongest 
correlations were observed between %pLDA and %LAA-950insp, %fLDA and %fGT, %LAA-856exp and 
FEV1/VC, and %LAA-856exp and FEV1/FVC. Conversely, poor correlations were observed between CT metrics 
of functional gas trapping (i.e. %fLDA and %fGT) and functional and CT parameters compatible with 
emphysema (i.e. DLco%, RV/TLC, and %LAA-950insp). CT metrics obtained by difference of density thresholds 
and those obtained by co-registration analysis correlated similarly with pulmonary function parameters. 
Figure 1 shows the scatterplot of the 202 patients using as coordinates %LAA-950insp and %LAA-856exp. The 
dispersion of data points increased progressively, with the increase in total gas trapping (%LAA-856exp), 
indicating that there was a wide grade of interaction of emphysematous and non-emphysematous contribution 
to total gas trapping. In particular, patients with similar values of %LAA-950insp had very different values in 
%LAA-856exp. The non-emphysematous contribution to total gas trapping is a function of the difference of the 
two variables at each level %LAA-950insp, as computed by %fGT. Figure 2 shows the strong correlation between 
%fGT and %fLDA, whose regression line essentially corresponds to the identity line.  
Figure 3 shows the relationship between %fGT, expression of functional gas trapping, and %LAA-950insp, 
expression of emphysematous gas trapping. As can be derived from the graphical subgrouping of patients 
shown in Figure 3, group Emph consisted of 29/202 (14.4%) patients with prevalent emphysema (%LAA-950insp 
higher than the mean value and %fGT lower than the mean value), whereas group Funct consisted of 46/202 
(22.8%) patients with prevalent functional (non-emphysematous) gas trapping (%LAA-950insp lower than the 
mean value and %fGT higher than the mean value). Groups Mixs 57/202 (28.2%) and Mixm 70/202 (34.6%) 
consisted of patients with a greater degree of severity of both components in group Mixs and a lower degree 
of severity of both components in group Mixm.  
Table 3 shows the mean values of anthropometric, smoking history, and pulmonary function data across 
the four groups (Emph, Mixs, Mixm, Funct in Figure 3). BMI was significantly higher in group Mixm 
(p<0.01), with a tendency to decrease as severity of disease increased. DLco% was the only parameter to differ 
significantly between group Emph and Funct (p<0.05).  
The logistic regression model was trained to classify COPD patients according to the probability to have a 
%LAA-950insp higher than the mean value of the sample. FEV1/VC, FEV1%, DLco%, and BMI were included 
as predictors of %LAA-950insp, and four groups were defined according to the probability output. The overall 
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accuracy of the probabilistic model was 81.1% in the training set and 79.2% in the validation set, with a higher 
accuracy (88.0%) in those patients with “milder” disease (probability of the output model <0.5) (Table 4). By 
combining functional indexes and BMI predictors, we classified each subject according to probability output 
values ranging from milder (group 1) to more severe (group 4) emphysema. The four outputs of the model had 
significantly different %LAA-950insp (or %pLDA) (p<0.01), as shown in panel A of Figure 4. Panel B of Figure 
4 shows the relationship between %fLDA and total gas trapping (%LAA-856exp). The different colors (from blue 
to yellow) correspond to the four groups of emphysema grade estimated by the model based on anthropometric 
and functional data. The regression line is fitted for data points with a model output less than 0.5 (r=0.89). 
Patients with milder emphysema (blue or dark-grey circles) are distributed mainly along the regression line. 
Conversely, patients with a more severe parenchymal destruction (light-grey or yellow circles) are scattered 
above the regression line. The data points distribution reveals that in this series of COPD patients, the 
emphysematous contribution to total gas trapping is absent for values of total gas trapping around or below 
30%. 
4.4 Discussion 
Our study provides evidence that imaging metrics obtained by density thresholds difference of inspiratory 
and expiratory CT scans can be used to identify and quantify the relative contribution of functional (non-
emphysematous) and emphysematous gas trapping and to identify a prevalent CT subtype. The evaluation of 
functional gas trapping obtained by density thresholds difference and co-registration analysis was comparable. 
The contribution of emphysema to total gas trapping, as assessed by CT, was estimated with reasonable 
accuracy by anthropometric and pulmonary function data. 
Airflow obstruction in COPD results from parenchymal destruction as well as from small conducting 
airway disease, with small airway disease preceding the development of parenchymal destruction (13-15). 
Both pathophysiologic processes lead to gas trapping into the lungs. The differentiation of emphysematous 
gas trapping (due to parenchymal destruction) from functional gas trapping (due to conductive airway disease) 
is difficult both by pulmonary function testing and CT scan (16, 17). Recently, the pPRMs obtained through 
co-registration analysis of inspiratory and expiratory CT scan overcame this issue, allowing discrimination of 
the two contributions to total gas trapping (2, 3, 18).  
We observed that the relationship between standard CT metrics (%LAA-950insp and %LAA-856exp) was greatly 
dispersed, suggesting that total gas trapping (%LAA-856exp) included both emphysematous and non-
emphysematous contributions. To determine these contributions we computed an index, called %fGT, derived 
from the difference between standard CT metrics (%LAA-950insp and %LAA-856exp) obtained from inspiratory 
and expiratory scans. The index had a strong correlation (r=0.99) with %fLDA, which is the reference 
parameter for the non-emphysematous gas trapping derived by co-registration (2, 3, 18-20). Likewise %fLDA, 
%fGT provides information on the amount of functional non-emphysematous gas trapping. In contrast to 
%fLDA, %fGT lacks localization of gas trapping. Gas trapping regional distribution can be provided only by 
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pPRM, and may play a role in the assessment of symptoms severity, as well as in the selection of patients for 
surgical and endoscopic lung volume reduction. However, %fGT can be easily obtained by using widely 
available software programs on lung density analysis. This measurement can be supplemented by the 
qualitative evaluation of the regional distribution of the lung pathologic changes. 
The weak correlation between CT metrics of parenchymal destruction (%LAA-950insp and %pLDA) and 
%fGT depicted the independent contribution of functional gas trapping and parenchymal destruction to airflow 
obstruction. This was in keeping with previous studies demonstrating weak correlations between indexes of 
emphysema severity and airway wall thickening (5, 21). 
The classification in four subgroups of patients (Emph, Mixs, Mixm, Funct) to assess the relative 
contribution of functional gas trapping and parenchymal destruction in the definition of COPD subtypes was 
very similar to that proposed in other studies (14, 21, 22). Our patients displayed a continuous spectrum of 
pathologic alterations of both conductive airway disease and emphysema. However, knowledge of the 
percentage of lung destruction may be of help in assessing patient prognosis and, possibly, in selecting the 
individual treatment (e.g. whether to add inhaled steroids to bronchodilators). Across the four subgroups of 
COPD patients we observed no statistically significant differences in smoking history. Statistically significant 
higher DLco% values were found in patients with prevalent functional (Funct) than in those with prevalent 
emphysema (Emph). Patients with milder disease (Mixm) had significantly higher BMI values than other 
subgroups. In agreement with previous studies, we found an inverse relationship between BMI and CT indexes 
of emphysema, including %LAA-950insp and %pLDA (22, 23). Accordingly, it is reasonable that BMI was 
included among the regressors of the probabilistic model to predict the contribution of emphysema to total gas 
trapping. It has very recently been shown that BMI as well as height itself (the denominator in the BMI 
formula) can be used to predict emphysema risk, with odds of emphysema increasing by 5% along with one 
cm increase in body height (24).  
Probabilistic models may help to characterize, without CT, the main pathophysiologic mechanism 
underlying airflow obstruction and may facilitate individualized treatment strategies. This may be of relevance 
considering the high prevalence of COPD in the general population and the unavailability of CT scan in most 
patients, even more if we consider that both inspiratory and expiratory scans are needed. We found that BMI 
combined in a predictive model with DLco%, FEV1, and FEV1/VC can be used to classify COPD patients 
according to CT parenchymal destruction (%LAA-950insp) with an acceptable level of accuracy. Previous studies 
have shown that parenchymal destruction on CT is related to both DLco% and FEV1, and that FEV1/VC is 
better related to CT indexes (%LAA-950insp) of airway obstruction with respect to FEV1/FVC (25, 26). 
According to previous results, spirometric indexes of airflow obstruction had a moderate inverse correlation 
with emphysema indexes on CT (27). These findings can be explained by the absence of a linear correlation 
between pulmonary function data and CT attenuation values, as demonstrated in a previous analysis (26). 
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The probabilistic index described here may help to differentiate, with acceptable approximation, the 
contribution of emphysema to total gas trapping in COPD. In patients with a predicted probability lower than 
0.5 as output of the model, functional gas trapping approximately corresponded to total gas trapping. In patients 
with a predicted probability greater than 0.5 as output of the model, parenchymal destruction added to 
functional gas trapping increasing the overall value of total gas trapping (%LAA-856exp). This is in keeping with 
the results obtained by McDonough and colleagues, who by measuring mean linear intercept on microCT 
showed that the narrowing and loss of terminal bronchioles preceded emphysematous destruction in COPD 
(15). In our patients, when total gas trapping was around or below 30% it had no significant emphysematous 
contribution, being derived almost completely from the non-emphysematous component. 
The main limitation of our study was the relatively small number of patients included in the cohort to be 
considered representative of the whole spectrum of COPD lung structural changes. Although our cohort was 
smaller than those of other studies (i.e. COPDGene, SPIROMICS), both the distribution and the mean of 
%LAA-950insp and %LAA-856exp obtained in our patients are comparable to those obtained in the COPDGene 
study, making the described model possibly suitable for application to other populations (28, 29). Another 
limitation of this study was the use of the fixed ratio FEV1/FVC according to GOLD guidelines to enroll 
patients, instead of using age-dependent reference equations such as the lower limit of normality (30, 31). The 
adoption of the fixed ratio may have over-diagnosed elderly patients, that represent the vast majority of our 
population. As far as CT was concerned, we lacked spirometric control of the level of lung inflation during the 
acquisition, and this may be an issue for reproducibility and data interpretation. However, all patients received 
careful instructions on how to perform the respiratory maneuvers while lying supine in the CT scanner. The 
presence of bronchiectasis and mucous impaction could have been another possible pitfall in the evaluation of 
lung density. However, none of our patients were studied during an exacerbation. Finally, the validation of the 
Logit model has been done on a training set (our cohort) and cross-validated by 10-fold leave-out test. It would 
be advisable to recruit a larger population in the near future, and to validate prospectively the model in a 
population different from that of the model derivation. A further limitation is the inclusion of only white 
Caucasian patients, which may limit the application of the observed associations to other ethnicities. 
In conclusion, our study demonstrated that standard imaging metrics obtained by inspiratory and expiratory 
thoracic CT scans can be used to identify and quantify the relative contribution of emphysematous and non-
emphysematous gas trapping, permitting a better definition of COPD subtypes. Co-registration analysis adds 
information on regional distribution of disease type, extent, and severity, which cannot be provided by standard 
densitometric analyses. Furthermore, the use of a probabilistic model including anthropometric and functional 
data can grade the relative contribution of parenchymal destruction to total gas trapping as assessed using CT. 
The application of this model may help in the definition of different COPD subtypes and may be used to design 
newer outcomes in developing clinical and pharmacologic trials.   
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4.5 Tables 
Table 1. Anthropometric, pulmonary function, and CT metrics data of 202 patients with COPD. Data are 
reported as mean ± SD. (*: quantitative CT data calculated by Apollo 2.1 VIDA Software; †: quantitative CT 
data calculated by LDA Imbio Software; %fGT is calculated as described in the Materials and Methods 
section)  
Age (years) 70.3 ± 8.1 
BMI (kg/m2) 26.3 ± 4.6 
Smoking history (Pack-years) 50.8 ± 25.5 
FEV1% 62.7 ± 26.3 
FEV1/VC (%) 47.1 ± 12.9 
FEV1/FVC (%) 51.4 ± 12.4 
FVC% 92.8 ± 25.0 
FRC% 128.6 ± 33.8 
TLC% 107.7 ± 17.6 
DLco% 68.5 ±23.6 
RV% 136.8 ± 48.3 
RV/TLC (%) 50.2 ± 17.1 
%LAA-950insp* 14.9 ± 12.4  
%LAA-856exp* 45.1 ± 20.5 
%Normal lung †  49.9 ± 21.1 
%fLDA† 36.1 ± 14.0 
%pLDA† 12.4 ± 12.7 
%fGT 36.2 ± 13.6 
 Legend: BMI = body mass index, DLco% = percentage of predicted diffusing capacity of lung for carbon monoxide, 
FEV1% = percentage predicted forced expiratory volume in 1 second, %fGT = percentage of functional gas trapping, 
%fLDA = percentage of functional low density area, FRC% = percentage of predicted functional residual capacity, FVC% 
= percentage of predicted forced vital capacity, %LAA-950insp = percentage of lung attenuation area with values below -
950HU at inspiratory CT scan, %LAA-856exp = percentage of lung attenuation area with values below -856HU at expiratory 
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CT scan, %pLDA = percentage of persistent low density area, RV% = percentage of predicted residual volume, TLC% = 
percentage of predicted total lung capacity, VC = vital capacity 
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Table 2. Pearson's correlation coefficients between %fGT and anthropometric, smoking history, pulmonary 
function, and CT imaging data. (*: p<0.01; †: p<0.05). 
 %LAA-950insp %pLDA %LAA-856exp %fLDA %fGT 
Age 0.05 0.04 0.06 0.07 0.04 
BMI -0.36* -0.37* -0.38* -0.22* -0.24* 
Pack-years 0.09 0.10 0.05 -0.02 -0.004 
FVC% -0.17† -0.20* -0.26* -0.21* -0.23* 
FEV1% -0.48* -0.50* -0.58* -0.43* -0.44* 
FEV1/VC -0.63* -0.64* -0.73* -0.52* -0.52* 
FEV1/FVC -0.66* -0.68* -0.72* -0.48* -0.48* 
TLC% 0.34* 0.33* 0.42* 0.33* 0.33* 
RV% 0.41* 0.43* 0.54* 0.42* 0.43* 
RV/TLC 0.35* 0.37* 0.42* 0.31* 0.31* 
FRC% 0.49* 0.50* 0.57* 0.40* 0.41* 
DLco% -0.43* -0.45* -0.43* -0.24* -0.25* 
%LAA-950insp 1 0.99* 0.76* 0.26* 0.24* 
%LAA-856exp 0.76* 0.76* 1 0.81* 0.81* 
%fLDA 0.26* 0.25* 0.81* 1 0.99* 
%pLDA 0.99* 1 0.76* 0.25* 0.25* 
%fGT 0.24* 0.25* 0.81* 0.99* 1 
 Legend: BMI = body mass index, DLco% = percentage of predicted diffusing capacity of lung for carbon monoxide, 
FEV1% = percentage predicted forced expiratory volume in 1 second, %fGT = percentage of functional gas trapping, 
%fLDA = percentage of functional low density area, FRC% = percentage of predicted functional residual capacity, FVC% 
= percentage of predicted forced vital capacity, %LAA-950insp = percentage of lung attenuation area with values below -
950HU at inspiratory CT scan, %LAA-856exp = percentage of lung attenuation area with values below -856HU at expiratory 
CT scan, %pLDA = percentage of persistent low density area, RV% = percentage of predicted residual volume, TLC% = 
percentage of predicted total lung capacity, VC = vital capacity. 
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Table 3. Mean values of anthropometric, smoking history, and pulmonary function data among the four 
groups (Emph – prevalent emphysema; Mixs – mixed severe; Mixm – mixed mild; Funct– prevalent functional 
gas trapping) shown in Figure 3, derived by the different contributions of %fGT and %LAA-950insp parameters. 
Differences between groups were analyzed by ANOVA and Games-Howell post-hoc tests. (*: p<0.01; †: 
p<0.05; NS: not significant).  
 Emph Mixs Mixm Funct Differences 
Age (years) 70.2 71.2 68.9 71.1 NS 
BMI (kg/m2) 25.1 24.4 28.6 25.9 Emph-Mixm * 
Mixs-Mixm * 
Funct-Mixm * 
Pack-years 56.3 52 48.6 49.1 NS 
DLco% 55.2 59 81.4 67.3 Emph-Mixm * 
Mixs-Mixm * 
Funct-Mixm * 
Emph-Funct † 
FVC% 97.9 87.5 98.6 87.3 Mixs-Mixm † 
Mixm-Funct † 
FEV1% 61.1 46.7 79.5 58.1 Emph-Mixs † 
Emph-Mixm * 
Mixs-Mixm * 
Funct-Mixm * 
Mixs-Funct † 
FEV1/VC (%) 44.2 36.8 57.9 45.3 Emph-Mixs † 
Emph-Mixm † 
Mixs-Mixm * 
Mixs-Funct * 
Mixm-Funct * 
FEV1/FVC (%) 48.4 40.8 61.3 51.1 Emph-Mixs † 
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Emph-Mixm † 
Mixs-Mixm * 
Mixs-Funct * 
Mixm-Funct * 
TLC% 110.9 115.5 99.5 108.5 Emph-Mixm † 
Mixs-Mixm * 
Mixm-Funct † 
RV% 135.6 163 109.3 140.6 Mixs-Mixm * 
Mixs-Funct † 
Mixm-Funct * 
RV/TLC (%) 49.3 59.4 42.3 51.2 Mixm-Funct * 
Mixs-Mixm * 
FRC% 131.9 150.3 109.2 129.2 Emph-Mixm * 
Mixs-Mixm * 
Mixm-Funct * 
Mixs-Funct * 
Legend: BMI = body mass index, DLco% = percentage of predicted diffusing capacity of lung for carbon monoxide, 
FEV1% = percentage predicted forced expiratory volume in 1 second, FRC% = percentage of predicted functional 
residual capacity, FVC% = percentage of predicted forced vital capacity, RV% = percentage of predicted residual volume, 
TLC% = percentage of predicted total lung capacity, VC = vital capacity 
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Table 4. Predictors, odds ratios, and accuracy of the logistic regression model trained to classify COPD 
patients according to their parenchymal destruction (%LAA-950insp) contribution to total gas trapping. The best 
regressors were selected after a step-wise procedure. The model classification cut-off was the predicted 
probability value P=0.5. Patients in class 1 included those with P<0.5 (groups 1 and 2 in Figure 4) and patients 
in class 2 included those with P>0.5 (groups 3 and 4 in Figure 4). In parentheses are the results obtained after 
ten fold cross-validation.  
 
Predictors Odds Ratio p 
DLco% 0.98 0.03 
FEV1/VC 0.87 <0.01 
BMI 3.41 <0.01 
FEV1% 1.03 0.02 
 
 Model estimation (cut-off P = 0.5) 
Class 1  Class 2 % Accuracy 
Observed: Class 1 
                 Class 2 
103 14 88.0% (88.0%) 
24 61 71.8% (67.0%) 
Overall Accuracy 81.1% (79.2%) 
Legend: BMI = body mass index, DLco% = percentage of predicted diffusing capacity of lung for carbon monoxide, 
FEV1% = percentage predicted forced expiratory volume in 1 second, P= predicted probability; VC = vital capacity  
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4.6 Figures 
Figure 1. Distribution of 202 patients with COPD according to CT imaging metrics of %LAA-950insp and 
%LAA-856exp. The two variables showed a substantial dispersion of data points which increased progressively 
with increasing severity of CT metrics changes. Patients with similar values of %LAA-950insp had very different 
values in %LAA-856exp. 
 
Legend: %LAA-950insp = percentage of lung attenuation area with values below -950HU at inspiratory CT scan, %LAA-
856exp = percentage of lung attenuation area with values below -856HU at expiratory CT scan. 
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Figure 2. Relationship between %fLDA and %fGT. The correlation between the two variables was strong, 
with a very high Pearson r coefficient (r= 0.99), and a regression line essentially corresponding to the identity 
line.  
 
Legend: %fGT = percentage of functional gas trapping, %fLDA = percentage of functional low density area. 
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Figure 3. Distribution of patients according to %fGT and %LAA-950insp. The correlation between the two 
variables was very weak (r=0.24, p<0.01). Lines representing mean values of %LAA-950insp and %fGT divide 
the scatterplot into four groups: group Emph (prevalent emphysema, %fGT lower than the mean value and 
%LAA-950insp higher than the mean value), group Mixs (mixed-severe disease, both %fGT and %LAA-950insp 
higher than the mean values), group Mixm (mixed-mild disease, both %fGT and %LAA-950insp lower than the 
mean values), and group Funct (prevalent functional gas trapping, %fGT higher than the mean value and 
%LAA-950insp lower than the mean value). 
 
Legend: %fGT = percentage of functional gas trapping, %LAA-950insp = percentage of lung attenuation area with values 
below -950HU at inspiratory CT scan. 
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Figure 4. A) Modified box-and-whiskers plot of mean values with corresponding 95% CI. The plot shws 
the distribution of %LAA-950insp across the four probability output groups of the logistic regression model. 
Group 1 (n=63, blue dot) represents a predicted probability output between 0 and 0.2, group 2 (n=61, dark 
grey dot) between 0.2 and 0.5, group 3 (n=44, light grey dot) between 0.5 and 0.8, and group 4 (n=34, yellow 
dot) between 0.8 and 1. These groups have significantly different %LAA-950insp (p<0.01). B) Relationship 
between %LAA-856exp and %fLDA across the four output groups of the logistic regression model. Patients with 
milder emphysema (blue circles) are distributed along the regression line (r=0.89), whereas patients with more 
severe parenchymal destruction (light grey and yellow circles) are scattered from this fitted line.  
 
Legend: %fLDA = percentage of functional low density area, %LAA-950insp = percentage of lung attenuation area with 
values below -950HU at inspiratory CT scan, %LAA-856exp = percentage of lung attenuation area with values below -
856HU at expiratory CT scan. 
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4.8 Supplemental Material 
4.8.1 Methods 
Patients were recruited at the Respiratory Unit of the University of Florence (181 patients) and at the 
Respiratory Unit of the Catholic University of Sacred Heart in Rome (43 patients). Clinical and pulmonary 
function data were acquired by pulmonologists (mean years of experience: 22.5 [10 to 40]), whereas 
radiologists (mean years of experience: 12.5 [5 to 20]) performed CT scans and post-processing image 
analysis. 
4.8.1.1 Pulmonary Function Testing 
All patients underwent pulmonary function evaluation using a mass-flow sensor and multi-gas analyzer (in 
Florence: V6200 Autobox Body Plethysmograph; Sensor Medics, Yorba Linda, USA; in Rome: Platinum 
Elite™ Body Plethysmograph, Medical Graphics Corporation, St. Paul, MN, USA). Blood gas analysis at rest 
was also performed by using a blood gas analyzer (in Florence: Radiometer ABL90 FLEX, Brønshøj, 
Denmark; in Rome: Radiometer ABL800 FLEX, Brønshøj, Denmark). 
4.8.1.2 Co-registration analysis 
To quantify the contribution of non-emphysematous gas trapping to total gas trapping, we introduced an 
index (called %fGT in the main part of the paper) calculated from standard CT metrics (%LAA-856exp and 
%LAA-950insp). The index %fGT was validated by comparison with %fLDA obtained by co-registration.  
4.8.1.3 Functional-based classification  
Considering the high prevalence of COPD in general practice [1E] and the unavailability of CT scans in 
the vast majority of patients, we also evaluated the possibility to estimate the severity of parenchymal 
destruction, as quantified by %LAA-950insp, using functional data routinely measured in clinical practice. In 
particular, we trained a logistic regression probabilistic model to classify patients according to the CT level of 
parenchymal destruction using anthropometric, clinical, and functional data as independent variables. The 
most statistically significant regressors of the model were identified by a step-wise procedure. Ten-fold 
validation was then performed to ascertain the total and partial predictive accuracy [2E]. One-way ANOVA 
(F-test) was used to verify the model performances in grading COPD patients according to the predicted 
probability (P) obtained as outputs. After the logistic regression model (Table 4 in main paper) was validated, 
we classified each subject according to the probability output value obtained by combining functional indexes 
and BMI predictors. Differences between groups of patients with progressively increasing severity of 
emphysema were assessed by ANOVA and F-test.  
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4.8.2 Results 
4.8.2.1 Co-registration analysis 
Figure 1E shows the distribution of the two pPRM indexes plotted with different colors according to FEV1% 
predicted grade. As shown in the figure, patients with similar FEV1 grade are randomly scattered in the 
diagram. The two different contributions to gas trapping could not be correctly assessed by using standard 
classification methods based on FEV1% thresholds. The two relative contributions to total gas trapping were 
weakly correlated (r=0.24, p<0.01, Table 2 of main manuscript). Lines in Figure 1E represent mean values of 
%pLDA (12.4%) and %fLDA (36.1%), dividing the scatterplot into four groups, in parallel with the division 
done in Figure 3 in the main manuscript. The four groups include Emph (prevalent emphysema, %fLDA lower 
than the mean value and %pLDA higher than the mean value), group Mixs (mixed-severe disease, both %fLDA 
and %pLDA higher than the mean values), group Mixm (mixed-mild disease, both %fLDA and %pLDA lower 
than the mean values), and group Funct (prevalent functional gas trapping, %fLDA higher than the mean value 
and %pLDA lower than the mean value). The distribution of the data points was very similar to that of Figure 
3 in the main manuscript. The small differences in data distribution were due to the differences in the mean 
value of %pLDA and %LAA-950insp (12.4% and 14.9%, respectively), while the mean values of %fLDA and 
%fGT were almost identical (36.1% and 36.2%, respectively). 
4.8.2.2 Functional-based classification 
Differences between the mean values of %LAA-950insp in the various groups are plotted in Figure 4 in the 
main text. Panel B of Figure 4 shows the relationship between %fLDA (x axis) and the total gas trapping 
amount as measured at expiration (y axis). The different colors (from blue to yellow) correspond to the four 
groups we introduced to grade emphysema extent estimation according to the output of the logistic regression 
model. 
The regression line is fitted for data points characterized by a predicted probability P value (model output) 
less than 0.5 classified as having “milder emphysema” extent. As shown in the figure, patients with milder 
emphysema (blue dots) are distributed along this regression line, so that the total gas trapping is directly 
associated with functional gas trapping (the emphysematous contribution is absent). Other patients, 
characterized by a more severe parenchymal destruction (light grey-yellow dots), are scattered far from this 
fitted line because the contribution of the emphysematous gas trapping caused a “shifting effect” towards 
higher values of %LAA-856exp (y values).  
 
Figure 1E. Distribution of the two pPRM indexes plotted with different colors according to FEV1% 
predicted grade. Lines representing the mean values of %pLDA (12.4%) and %fLDA (36.1%) divide the 
scatterplot into four groups, in parallel with the division done in Figure 3 in the main manuscript. The four 
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groups include group Emph (prevalent emphysema, %fLDA lower than the mean value and %pLDA higher 
than the mean value), group Mixs (mixed-severe disease, both %fLDA and %pLDA higher than the mean 
values), group Mixm (mixed-mild disease, both %fLDA and %pLDA lower than the mean values), and group 
Funct (prevalent functional gas trapping, %fLDA higher than the mean value and %pLDA lower than the mean 
value).  
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4.10 Advances in knowledge 
- As shown in 202 patients with COPD, the quantification of the relative contributions of emphysematous 
and non-emphysematous gas trapping was used to identify a prevalent CT subtype. 
- The emphysematous (persistent low density area, %pLDA) and non-emphysematous (functional low 
density area, %fLDA) contributions to total gas trapping provided by a pulmonary parametric response 
map (pPRM) could not be adequately assessed by standard classification methods based on FEV1%, 
which showed only a moderate correlation with %pLDA (r=-0.50) and %fLDA (r=-0.43).  
- The non-emphysematous contribution to total gas trapping (%fLDA) was highly correlated (r=0.99), 
with the difference of imaging metrics at standard density thresholds (%LAA-856exp and %LAA-950insp). 
- The emphysematous contribution to total gas trapping (%pLDA) was essentially absent for values of 
total gas trapping around or below 30%. 
- A functional model including FEV1/VC, FEV1%, DLco%, and BMI was used to predict the CT level 
of parenchymal destruction, with an overall accuracy of 81%. 
Implications for Patient Care: 
- The definition of the prevalent CT subtype (i.e. emphysema versus airway disease) of COPD obtained 
by a co-registration method as well as by standard CT metrics could potentially be used to target patient 
therapy to the underlying COPD endotype. 
- A logistic model combining BMI and pulmonary function data can be used to predict CT-based 
quantification of emphysema grade, which may prove useful when assessing COPD patients who do 
not undergo thoracic CT. 
Summary Statement: 
Standard imaging metrics obtained by inspiratory and expiratory CT can be used to identify and quantify 
the relative contribution of emphysematous and non-emphysematous gas trapping, permitting a better 
definition of COPD patient subtypes. 
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Chapter 5 - Statistical models: lung function and BMI 
In the previous study we have shown that a probabilistic model based on body mass index (BMI), FEV1 as 
percent of predicted, FEV1/VC and DLco as percent of predicted could be used to estimate emphysema 
quantified on CT. Limitations of that approach for clinical practice or clinical trials are that DLco is not always 
available and standard pulmonary function parameters have a wide inter-individual variability, even after 
normalization for ethnicity, age, and body size.  
We aimed to ascertain whether the probability of having emphysema, as defined by quantitative CT metrics, 
could also be estimated with a level of accuracy suitable for clinical practice and pharmacologic trials by a 
probabilistic model based on functional parameters directly derived from the spirometric flow-volume curve 
without standardization for sex, age, and ethnicity data. 
Lung function and BMI predictive models to assess CT emphysema extent in COPD 
Mariaelena Occhipinti, M Paoletti, F Bigazzi, J Sieren, M Palazzi, G Camiciottoli, M Pistolesi 
(Presentation at American Thoracic Society Conference, San Diego, 22-24/05/2018) 
 
5.1 Background 
Airflow limitation in COPD results from lung parenchymal destruction (emphysema) as well as from 
conductive airway disease. These two pathophysiologic conditions lead both to gas trapping within lungs. 
Spirometry cannot differentiate between emphysematous and functional gas trapping, whereas chest computed 
tomography (CT) with post-processing image analysis can quantify both components of gas trapping.  
 Although in each patient one of the two pathophysiologic conditions (endotypes) may prevail, either 
emphysema or conductive airway disease, most COPD patients present with a mixed phenotype characterized 
by various combinations of both components and a corresponding mixed CT subtype. Knowledge of the 
prevalent subtype in each patient may be of interest in developing clinical and pharmacological trials designed 
to target patients therapy to the underlying pathophysiologic mechanism of airflow obstruction. However, CT 
cannot be performed in all COPD patients, due to the high prevalence of COPD in the general population and 
the unavailability of CT scans in the vast majority of patients.  
Purpose: We aimed to predict by clinical and functional data the probability of having emphysema, as 
assessed on CT. 
5.2  Methods 
From January 2014 to December 2017 we recruited 133 non-consecutive COPD patients with the following 
criteria. 
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Inclusion criteria:  
- Age 40 to 85 years  
- Smoking history of more than 10 pack-years 
- Nonreversible post-bronchodilator airflow obstruction at PFTs 
- GOLD stages I to IV 
- Chest CT within 48 hours from pulmonary function evaluation 
Exclusion criteria:  
- History of exacerbation within one month  
- History of any clinical conditions interfering with pulmonary function or chest CT quantitative 
parameters assessment, including asthma, diffuse bronchiectasis, interstitial lung disease, acute heart 
failure, chemo-radiation therapy, lung cancer, lung surgery, metal objects in the chest. 
5.2.1 Pulmonary Function Tests (PFTs) 
All patients underwent complete pulmonary function evaluation within 48 hours of the CT examination. 
Pre-and post-bronchodilator spirometry data, static and dynamic lung volumes (FEV1, FEV1/VC, FEV1/FVC, 
VC, RV, TLC, RV/TLC, FRC), and single-breath diffusing capacity for carbon monoxide (DLco) were 
measured according to ATS/ERS guidelines. We also measured the lower limit of normality (LLN) according 
to ERS/ATS guidelines. 
5.2.2 Chest CT Scan 
Volumetric chest CT scans were obtained at full inspiration and expiration using the acquisition protocol 
adopted in the COPDGene study. All CT scans were performed by using the same CT scanner for all patients 
(SOMATOM Sensation 64, Siemens, Erlangen, Germany).  
Patients received prior cautious instructions on how to perform the respiratory maneuvers while lying 
supine in the CT scanner with arms fully abducted. No contrast medium was administered.  
The relative volumes of lung attenuation area with values below -950 HU at inspiration (%LAA-950insp) and 
below -856 HU at expiration (%LAA-856exp) were quantified by using the Pulmonary Workstation Apollo 2.1 
(VIDA Diagnostics, Coralville, Iowa, USA). Thresholds at -950 Hounsfield Units (HU) and -856 HU were 
chosen as densitometric cut-off consistent with emphysema and total gas-trapping, respectively.  
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5.2.3 Predictive model 
 The CT level of parenchymal destruction was estimated by a ten-fold validated logistic regression model 
built from stepwise selection of anthropometric, clinical, and functional data. The most significant regressors 
of the model were identified by a step-wise procedure. Ten-fold validation was then performed to ascertain the 
total and partial predictive accuracy. The logistic regression model was trained to classify COPD patients 
according to the probability to have a %LAA-950insp higher than the mean value of the sample. By applying the 
model, each subject was classified according to probability output (pth) values, from milder (pth<0.5) to more 
severe (pth>0.5) emphysema.  
 After the logistic regression model was validated, we classified each subject according to the pth value 
obtained by combining functional indexes and BMI predictors. ROC curve (AUC) analysis was used to 
calculate the accuracy of the models after tenfold cross-validation considering the logistic pth at value of 0.5. 
The software programs included Mathcad (version 2001; Mathsoft), SPSS/PC WIN 11.5.1 (SPSS, Chicago, 
IL), and C++ programming language. Values of p lower than 0.05 indicated statistical significance.  
5.3 Results 
Anthropometric, clinical, functional, and imaging data of patients with FEV1/FVC<0.70 or 
FEV1/FVC<LLN.  
 
Anthropometric, clinical, functional, and imaging data of 133 patients with FEV1/FVC<0.70  
Age 70 (8) FEV1% 63 (27)  FVC % 93 (25) RV % 137 (48) Imaging 
BMI 26 (5) FEV1/VC 47 (13) FRC % 129 (34) RV/TLC 50 (17) %LAA-950insp 15 (12) 
Pack/yrs  51 (25)  FEV1/FVC 51 (12) TLC % 108 (18) DLco % 68 (24) %LAA-856exp 45 (20) 
Data are expressed as means (SD). 
Anthropometric, clinical, functional, and imaging data of 108 patients with FEV1/FVC<LLN 
Age 70 (8) FEV1% 56 (23)  FVC % 93 (25) RV % 146 (45) Imaging 
BMI 26 (5) FEV1/VC 44 (12) FRC % 136 (32) RV/TLC 53 (14) %LAA-950insp 16 (12) 
Pack/yrs  51 (24)  FEV1/FVC 49 (12) TLC % 111 (17) DLco % 64 (22) %LAA-856exp 49 (19) 
Predictors of %LAA-950insp in the two models, contingency tables and corresponding ROC curves in the 
group of patients with FEV1/FVC<0.70 
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MODEL A 
  
MODEL B 
  
 
MODEL A                                                                       MODEL B 
 
The concordance between the two models in the group of 133 patients with FEV1/FVC<0.70 was 84%. 
In the group of 108 patients with FEV1/FVC<LLN both models had 81% accuracy. The concordance 
between the two models in the group of patients with FEV1/FVC<LLN was 81%. 
5.4 Conclusions 
The predictive models including BMI and functional data predicted with a considerable accuracy the 
emphysema extent as assessed on quantitative CT, regardless of the criteria used for recruiting patients with 
COPD. These models, if validated in larger scale studies, may be suitable for daily clinical assessment of 
patients with COPD, to predict treatment response, and to design newer outcomes for clinical and 
pharmacologic trials in which CT scan cannot be performed. 
A B
A 
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Chapter 6 - Statistical models: maximal expiratory flow-
volume curve 
In the previous study we have shown that the probabilistic models including BMI and functional data can 
estimate with a considerable accuracy the emphysema extent as assessed on quantitative CT, regardless of the 
criteria used for recruiting patients with COPD. The importance of the maximal expiratory flow-volume 
(MEFV) curve parameters lead us towards an accurate analysis of the flow-volume curve throughout its shape. 
Moreover, a method based on the MEFV curve has recently been proposed by Topalovic et al. to predict the 
presence of emphysema, showing good specificity but low sensitivity (1). 
We aimed to find from the analysis of MEFV curve the parameter(s) most suitable for a probabilistic model 
to predict with high specificity and sensitivity the presence and extent of emphysema, as defined by 
quantitative CT metrics. 
 
6.1 Methods 
This was a two-centre study approved by the institutional Ethics Committees of the University of Florence 
and the Catholic University of Sacred Heart in Rome. The study was based on a retrospective interpretation of 
prospectively acquired data. From January 2012 to December 2016, subjects with clinical diagnosis of COPD 
were considered for inclusion if they satisfied the following inclusion criteria: age 40-85 years, smoking history 
>10 pack-years, no COPD exacerbations within one month, no diagnosis of asthma or cardiac disease, and 
acceptance to participate by written informed consent. From a total of 232 eligible subjects, 38 were excluded 
because incomplete data, or coexisting abnormalities on CT scan, thus 194 were included in the study.  
6.1.1 Functional and imaging evaluation 
Subjects underwent complete pulmonary function evaluation by using a mass-flow sensor and multigas 
analyser (V6200 Autobox Body Plethysmograph Sensor Medics, Yorba Linda, USA, or Platinum Elite™ Body 
Plethysmograph, Medical Graphics Corporation, St. Paul, MN, USA), arterial blood gases by Radiometer 
ABL90 FLEX or ABL800 FLEX (Brønshøj, Denmark), and CT scan within 48 hours of the clinical and 
functional evaluation. Pre- and post-bronchodilator spirometry, lung volumes, and single-breath DLco were 
obtained according to standard ATS/ERS (American Thoracic Society/European Respiratory Society) 
recommendations (8-10). 
In each center volumetric chest CT scans were obtained by the same team and the same CT scanner 
(SOMATOM Sensation 64, Siemens, Erlangen, Germany, or SOMATOM Definition FLASH 128, Siemens, 
Erlangen, Germany). CT scans were acquired at full inspiration and forced end-expiration using the acquisition 
protocol adopted in the COPDGene Study (11) with the following parameters: 120 kVp, 200 mAs, rotation 
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time 0.5s, slice thickness 0.6mm, pitch 1.1 and reconstructions kernels b31f (smooth) and b70f (sharp). 
Subjects were instructed on how to perform respiratory manoeuvres while lying supine in the CT scanner with 
arms fully abducted. No contrast medium was injected. Post-processing image analysis was performed with 
reconstruction kernel b31f. Thresholds at -950 Hounsfield Units (HU) and -856 HU were chosen as 
densitometric cut-offs for emphysema and total gas trapping, respectively (12-14). The relative volumes of 
lung attenuation area with values below -950 HU at inspiration (%LAA-950insp) and below -856 HU at expiration 
(%LAA-856exp) were quantified by using the Pulmonary Workstation Apollo 2.1 (VIDA, Coralville, IA, USA). 
Percentage of functional gas trapping (%fGT) was calculated as %fGT = %LAA-856exp – %LAA-950insp – 6%, 
which was validated and found strongly correlated (r2=0.98) with functional low density area (%fLDA) 
measured by co-registration analysis of paired inspiratory and expiratory CT scans (15). %fGT is the lung area 
with low attenuation values below -856HU on expiration and above -950HU on inspiration, representing the 
fraction of gas trapped at end expiration because of airway closure or extreme flow limitation. 
6.1.2 Data analysis and statistics 
The relationship between %LAA-856exp and %LAA-950insp was analyzed by fitting a local regression curve 
to CT raw data.  
A binary logistic regression model was trained to classify all subjects according to the probability of being 
affected by less or more severe emphysema according to their value of %LAA-950insp lower or higher than the 
mean value of the group, matching the same classification criteria published for larger cohorts (16). The input 
parameters were selected by a step-wise process using anthropometric data and parameters derived from the 
MEFV curve as independent variables.  
The shape of the MEFV curve was analysed by fitting segments of the descending limb at specific fractions 
of FVC. Curves with a difference between PEF and FEF25 less than 5% of PEF were discarded by the 
algorithm. 
ROC curve (AUC) analysis was used to calculate the accuracy of the model after tenfold cross-validation 
considering a logistic probability threshold (pth) at value of 0.5. 
Welch's t-test was used to evaluate differences in CT metrics among subgroups with different ranges of 
%LAA-950insp. Pearson r coefficient was used to describe the correlations between CT parameters.  
The software programs included Mathcad (version 2001; Mathsoft), SPSS/PC WIN 11.5.1 (SPSS, Chicago, 
IL), and C++ programming language. Values of p lower than 0.05 indicated statistical significance. Data are 
expressed as mean and standard deviation (SD). 
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6.2 Results 
Scatterplot of CT imaging metrics of %LAA-950insp and %LAA-856exp showed a non-linear monotonic 
relationship with two main segments with distinct slopes, different dispersion profiles (r2= 0.45 p<0.01 and 
r2= 0.30 p<0.01), and a breakpoint at the mean %LAA-950insp (14%) (Figure 1). In the group of 77 subjects with 
%LAA-950insp >14 the data points around the relative segment of the regression curve were more dispersed than 
in the group of 117 subjects with %LAA-950insp <14 (Figure 1). CT metrics, anthropometric and functional 
parameters were significantly different (p<0.05) between the two groups (Table 2). 
There was a significant correlation between %fGT and %LAA-856exp in both groups, but it was much stronger 
(r2= 0.96) in the group of subjects with %LAA-950insp <14 than in those with %LAA-950insp >14 (r2= 0.45). This 
difference suggests that total gas trapping was completely explained by %fGT in the latter, but not in the 
former. 
A binary logistic regression model including the slope of the flow-volume curve between 25% and 50% of 
FVC [S25-50= (FEF25 – FEF50) / 0.25 x FVC], BMI, and FEV1/FVC predicted the probability of having 
emphysema with 87% sensitivity and 81% specificity (85% accuracy). Examples of differences in MEFV 
curve of two subjects with different degrees of emphysema are shown in Figure 3.  
Figure 4 shows the scatterplot of %LAA-856exp vs %fGT relative to the model output of each patient.  
The vast majority of subjects with pth<0.5 were distributed along the identity line, suggesting that %LAA-
856exp was almost completely explained by %fGT, whereas most subjects with pth>0.5 were scattered above the 
identity line, suggesting that %LAA-856exp could be also explained by the emphysema contribution (Figure 4). 
The distance of each data point above the identity line gives an estimate of the contribution of emphysema to 
total gas trapping. 
6.3 Discussion 
The main finding of this study is that the probability of having emphysema, as defined by quantitative CT 
metrics, was estimated with accuracy by a probabilistic model including BMI and functional parameters 
derived from MEFV curve not requiring normalization by reference equations. 
Nowadays quantitative CT enables the definition of the relative volumes of emphysema and gas trapping 
in subjects with COPD by using CT metrics of low attenuation areas at inspiration (%LAA-950insp) and 
expiration (%LAA-856exp) (12, 13). In the present study a non-linear relationship between the above-mentioned 
CT metrics was observed with a breakpoint at 14 %LAA-950insp. This is close to the mean value observed in the 
COPDGene Study population (17) and recently proposed to define “severe” emphysema (16). The results of 
the present study show that this cut-off distinguished not only different degrees of emphysema, but also 
subjects with different mechanisms of airflow obstruction. Indeed, subjects with %LAA-950insp<14 had a 
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borderline (6.7%) percentage of emphysema (18) and their total gas trapping was almost completely explained 
by functional gas trapping, which was on average 34%, a value much higher than the 20% reported in healthy 
individuals (19). Therefore, in this group the gas trapping was mainly accounted for by conductive airway 
disease. Conversely, in subjects with %LAA-950insp >14 total gas trapping was mainly accounted for by the 
presence of emphysema, though it is not possible to exclude that functional gas trapping was also present due 
to coexisting airway disease or loss of airway support by peribronchial tethering (20).  
Traditionally, a reduction of DLco has been considered as a marker of emphysema in subjects with COPD 
(21). In this connection, a recent study from our group showed that a logistic model including DLco%, FEV1%, 
FEV1/VC, and BMI was able to accurately predict the presence of emphysema on CT (15). 
As early as in 1976, it was proposed that a kinging of the descending limb of the forced MEFV curve might 
represent a sign of airway collapse reflecting the presence of emphysema, as assessed by DLco (22). More 
recently the angle between two regression lines fitted to the descending limb of the MEFV curve resulted to 
be predictive of the presence of emphysema on CT scan, showing a good specificity but low sensitivity (1). 
The kinking of MEFV curve in emphysema can be interpreted on the grounds of the wave-speed theory (23). 
During forced expiration, alveolar pressure increases and gas is compressed within the lung, thus reducing 
lung volume and elastic recoil pressure. As a result, driving pressure and distending pressure at choke point 
are decreased, thereby reducing maximal flow. This effect may be magnified in emphysema because of the 
abrupt fall of lung elastic recoil at high lung volumes (21) and the larger amount of gas to be compressed, thus 
flattening the MEFV curve. By contrast, the scooping of MEFV curve in airway disease may reflect a smooth 
decrease of lung elastic recoil and a transition of the chock point towards the lung periphery with less gas 
compression. Mechanisms that may contribute to the kinking of forced expiratory flow in emphysema are a 
sudden airway narrowing due to sharp decrease in lung elastic recoil (24) and a sharp decrease of thoracic gas 
compression from mid to low lung volumes. Therefore, flattening of the MEFV curve from mid-to-low lung 
volumes should be a predictor of emphysema. In the present study, slopes of MEFV curves were determined 
at different lung volumes and compared with quantitative CT metrics to derive a probabilistic model for 
estimating the probability of having emphysema at CT. The logistic model of the present study predicted the 
presence of emphysema with sensitivity considerably higher than found by Topalovic et al. (1). Furthermore, 
the model described in the present study had slightly higher accuracy than the model previously described by 
our group based on BMI, FEV1%, FEV1/VC, and DLco% (15). Advantages of the present model over the 
previous one are that it does not require any normalization of parameters for anthropometric data and it is 
independent of the choice of spirometric criteria to define airflow obstruction. 
From a technical point of view the sensitivity of the model is critically dependent on the effort during the 
MEFV curve because this affects the magnitude of thoracic gas compression (25), which is a major determinant 
of the shape of MEFV curve, particularly in subjects with prevalent emphysema (Figure 2) (3). 
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This study has some limitations. First, it included a relatively small number of subjects, only white 
Caucasian, and cannot be considered representative of the whole spectrum of COPD subjects. However, the 
distribution of CT metrics and their average values were similar to that reported in the COPDGene Study, 
which included more than 10,000 subjects of two different ethnicities (17). Second, CT scans were acquired 
without spirometric control of lung inflation level during the acquisition. However, all subjects received prior 
cautious instruction on how to perform the respiratory manoeuvres just before undergoing CT scanning by 
dedicated personnel and quantitative measurements were obtained by using an objective and automated 
software using the thresholds for emphysema and gas trapping reported in current literature (12-14).  
In conclusion, this study demonstrates that the probability of having emphysema and its extent, as defined 
by quantitative CT metrics, can be estimated with accuracy by a probabilistic model based on BMI and 
functional parameters derived from the flow-volume curve. Being independent of reference values, the model 
could be helpful in clinical practice and also in patients’ selection for clinical trials.  
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6.4 Tables 
Table 1. Anthropometric, pulmonary function and CT metrics data. Data are mean (SD). Smoking history 
is expressed as pack-years.  
N 194 
Sex (M:F) 154:40 
Age (yr) 70.2 (8.0) 
BMI (kg/m2) 26.5 (4.6) 
Smoking history 51.7 (27.0) 
FEV1 (% pred) 62.6 (25.8) 
FEV1/VC 47.5 (13.2) 
FEV1/FVC 52.3 (13.1) 
TLC (% pred) 108.2 (16.5) 
DLco (% pred) 68.9 (23.5) 
RV (% pred) 137.0 (46.7) 
FRC (% pred) 129.5 (32.6) 
RV/TLC 49.9 (14.1) 
%LAA-950insp 14.3 (11.7) 
%LAA-856exp 45.2 (20.3) 
%fGT 36.9 (13.7) 
Legend: BMI = body mass index, DLco = lung diffusing capacity of lung for carbon monoxide, FEV1% = forced 
expiratory volume in 1 s, %fGT = percentage of functional gas-trapping, FRC = functional residual capacity, FVC = 
forced vital capacity, % LAA-950insp = percentage of lung attenuation area with values <-950 Hounsfield Units at 
inspiratory CT scan, %LAA-856exp = percentage of lung attenuation area with values <-856 Hounsfield Units at expiratory 
CT scan, RV = residual volume, TLC = total lung capacity, VC = vital capacity.  
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Table 2. Mean values of CT metrics, anthropometric and functional data in relation to emphysema extent 
(%LAA-950insp).  
 %LAA-950insp < 14 %LAA-950insp ≥ 
14 
 p 
N 117 77  
%LAA-950insp 6.7 25.9 <0.01* 
%LAA-856exp 34.5 61.4 <0.01* 
%fGT 33.8 41.5 <0.01* 
Age (yr) 69.2 71.6 0.04* 
BMI (kg/m2) 27.7 24.7 <0.01* 
Smoking history 49.7 54.7 0.19 
FEV1 (%) 70.2 50.9 <0.01* 
FVC (%) 92.8 92.9 <0.01* 
FEV1/VC 53.5 38.5 <0.01* 
FEV1/FVC 58.7 42.6 <0.01* 
TLC (%) 103.8 114.9 <0.01* 
RV (%) 125.1 155.1 <0.01* 
RV/TLC 46.3 55.5 <0.01* 
FRC (%) 118.0 146.8 <0.01* 
DLco (%) 77.6 55.9 <0.01* 
PEF (%) 77.9 54.5 <0.01* 
S25-50 (degrees) 65.1 37.7 <0.01* 
PEF= peak of expiratory flow, S75-50 = slope of the descending limb of flow-volume curve between 75 and 
50% of FVC. Other notations as in Table 1. 
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6.5 Figures 
Figure 1. Scatterplot of %LAA-950insp and %LAA-856exp in 194 patients with COPD. The local regression 
curve (grey line) of the two CT metrics depicts the non-linear monotonic relationship of the variables. The 
dashed line indicates the breakpoint corresponding approximately to the mean value of %LAA-950insp of the 194 
patients. Pearson's correlation coefficient value is r2= 0.45 (p<0.01) in the first segment and r2= 0.30 (p<0.01) 
in the second segment.  
 
 
Legend: %LAA-950insp = percentage of lung attenuation area with values below -950 Hounsfield Units at inspiratory CT 
scan; %LAA-856exp = percentage of lung attenuation area with values below -856 Hounsfield Units at expiratory CT scan. 
(Open circles are 37 subjects with FEV1/FVC<0.70 but greater than lower limit of normality) 
  
Phenotyping COPD: correlazione clinico-radiologica dei fenotipi della BPCO 
   Page 45 
Figure 2. ROC curves of the two logistic models. The curves represent the DLco-based model (left panel) 
and the MEFV curve-based model (right panel). 
 
 
 
 
Figure 3. Maximal expiratory flow-volume curves of two representative subjects, with severe emphysema 
(left panel: 24% LAA-950insp, 50% LAA-856) or airway disease (right panel: 4% LAA-950insp, 53% LAA-856exp). 
Note the flatter slope between 25 and 50% of FVC in the former when flow was plotted against expired volume 
(black lines) but not pletysmographic thoracic volume (grey lines), indicating greater thoracic gas compression 
at high-to-mid lung volumes. 
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Figure 4. Scatterplot of %LAA-856exp and %fGT with colours ranging from white to black according to the 
probability values estimated by the logistic model. Data points lying on the identity line indicate subjects in 
whom the total gas trapping can be totally explained by functional gas trapping. The distance of each data 
point above the identity line quantifies the contribution of emphysema to total gas trapping. 
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Chapter 7 - Mathematical model and radiomics 
In the previous studies we have shown that the statistical models including either BMI and functional data 
or parameters of the flow-volume curve can estimate with a considerable accuracy the emphysema extent as 
assessed on quantitative CT, regardless of the criteria used for recruiting patients with COPD (FEV1/FVC<0.70 
or FEV1/FVC<LLN). The most relevant limitation of these approaches is the intrinsic nature of the statistical 
models, namely they rely on regression coefficients reflecting the characteristics of the training set. 
Mathematical models can overcome this limitation and in the past they have been developed to study the 
biomechanical characteristics of the lung function.  
We aimed at developing a mathematical model, based on the analysis of the maximal expiratory flow-
volume (MEFV) curve, to provide an emphysema severity index (ESI) and to compare it with the COPD 
subtypes defined by quantitative CT and CT-based radiomics. 
 
Spirometric assessment of emphysema presence and severity as measured by  
quantitative CT and CT-based radiomics in COPD 
Mariaelena Occhipinti, Matteo Paoletti, Brian J. Bartholmai, Srinivasan Rajagopalan, Ronald A. Karwoski, 
Cosimo Nardi, Riccardo Inchingolo, Anna R. Larici, Gianna Camiciottoli, Federico Lavorini, Stefano Colagrande, Vito 
Brusasco, Massimo Pistolesi 
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7.1 Introduction 
Chronic obstructive pulmonary disease (COPD) is a complex condition with a wide spectrum of clinical 
presentations and pathological features unified under the spirometric definition of airflow obstruction. Airway 
narrowing and parenchymal destruction are recognized as the mechanisms responsible for airflow obstruction 
in COPD, but they cannot be distinguished by standard spirometry. However, standard spirometry is one of 
the most employed variables for patients enrollment and outcome evaluation in clinical and pharmacologic 
studies.  
In recent years, chest computed tomography (CT) allows to depict and measure in vivo the lung pathologic 
changes of COPD by quantifying parenchymal destruction, the direct sign of emphysema, as well as bronchial 
wall thickening and gas trapping, which represent direct and indirect signs of conductive airway disease, 
respectively. (1,2) A closer imaging definition of whether conductive airway disease or emphysema is the 
predominant mechanism of airflow obstruction has been lately obtained by using co-registration analysis of 
inspiratory and expiratory CT scans. (3) Nowadays more information is extracted from imaging data using 
advanced feature analysis representing what is called “radiomics”. (4) Artificial neural networks and statistical 
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models are available to provide radiologists and clinicians with objective and reproducible computer-based 
evaluations of lung parenchyma. In particular, CALIPER (Computer Aided Lung Informatics for Pathology 
Evaluation and Rating) recently developed at Mayo Clinic (Rochester, MN), is a computational platform for 
the near real-time characterization and quantification of lung parenchymal patterns on CT scan. (5,6) 
Altogether, quantitative and qualitative studies have shown that CT can allow distinguishing not only 
between airway and parenchymal abnormalities, but also between subtypes of emphysema, i.e. centrilobular, 
panlobular, and paraseptal. (7) However, a widespread routine use of CT for the assessment of COPD in 
clinical practice and clinical and pharmacologic studies cannot be currently foreseen due to radiation exposure 
and limited instrumental availability in the face of the COPD rapidly increasing prevalence of the disease. (8) 
In a previous study we have shown that a probabilistic model based on body mass index, FEV1 as percent 
of predicted, FEV1/VC and DLco as percent of predicted could be used to estimate emphysema quantified on 
CT. (9) Limitations of that approach for clinical practice or clinical and pharmacologic trials are that DLco is 
not always available and that standard pulmonary function parameters have a wide inter-individual variability, 
even after normalization for ethnicity, age, and body size. (10) Furthermore, probabilistic models rely on 
regression coefficients that reflect the characteristics of the training set. These limitations may be possibly 
overcome by mathematical models studying directly the biomechanical characteristics of airway function of 
each patient. (11) 
The aim of the present study was to assess whether a mathematical model designed to fit the shape of the 
maximum expiratory flow-volume curve (MEFV) obtained by standard spirometry could provide estimates of 
the presence and the severity of emphysema comparable with parameters used to assess emphysema extent 
derived from quantitative CT and CT-based radiomics.  
7.2 Methods 
This two-center study was approved by the institutional Ethics Committees of the University of Florence 
and of the Catholic University of Sacred Heart in Rome. The study is based on a retrospective interpretation 
of prospectively acquired data. From January 2012 to December 2016, subjects with diagnosis of COPD (post-
bronchodilator FEV1/VC<0.70) (12,13) were considered for inclusion if they satisfied the following inclusion 
criteria: age 40-85 years, smoking history >10 pack-years, no COPD exacerbations within one month, no 
diagnosis of asthma or cardiac disease, and acceptance to participate by written informed consent. Thirty-eight 
out of 232 eligible subjects were excluded because of incomplete data or coexisting abnormalities on CT scan.  
7.2.1 Functional evaluation 
Subjects underwent complete pulmonary function evaluation by using a mass-flow sensor and multigas 
analyser (V6200 Autobox Body Plethysmograph Sensor Medics, Yorba Linda, CA, USA, or Platinum Elite™ 
Body Plethysmograph, Medical Graphics Corporation, St. Paul, MN, USA), arterial blood gases by 
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Radiometer ABL90 FLEX or ABL800 FLEX (Brønshøj, Denmark). Pre- and post-bronchodilator spirometry, 
lung volumes, and single-breath DLco were obtained according to standard ATS/ERS (American Thoracic 
Society/European Respiratory Society) recommendations. 14 
7.2.2 CT scanning technique and analysis 
In each center volumetric chest CT scans were obtained by the same team and the same CT scanner 
(SOMATOM Sensation 64 or SOMATOM Definition FLASH 128, Siemens, Erlangen, Germany) within 48 
hours of the functional evaluation. CT scans were acquired at full inspiration and forced end-expiration using 
the acquisition protocol adopted in the COPDGene Study (15) with the following parameters: 120 kVp, 200 
mAs, rotation time 0.5 sec, slice thickness 0.6 mm, pitch 1.1 and reconstructions kernels b31f (smooth) and 
b70f (sharp). Subjects were instructed on how to perform respiratory maneuvers while lying supine in the CT 
scanner with arms fully abducted. No contrast medium was injected. Post-processing image analysis was 
performed on images with reconstruction kernel b31f by using three different software programs: VIDA, Imbio 
LDA, CALIPER (Figure 1A-F). 
- VIDA analysis (Figure 1B). We used the Pulmonary Workstation Apollo 2.1 (VIDA, Coralville, IA, 
USA) installed onsite to segment airways and lungs and to calculate the relative volumes of lung 
attenuation area with values below -950 Hounsfield Units (HU) at inspiration (%LAA-950insp) and below -
856HU at expiration (%LAA-856exp). Thresholds at -950 HU and -856HU were chosen as densitometric 
cut-offs for emphysema and total gas trapping, respectively. (1,16,17) The analysis was fully automated 
with the possibility to correct manually any mistake in airway or lobe segmentation. 
- Imbio LDA analysis (Figure 1C-D). Co-registration analysis performed by Imbio LDA 
(Minneapolis, MN, US) automatically pairs inspiratory and expiratory CT scans to provide percentages 
of normal lung (percentage of voxels with CT attenuation greater than -950 HU at inspiration and greater 
than -856HU at expiration), persistent low density area (%pLDA, voxels with CT attenuation below -
950HU at inspiration and below -856HU at expiration), and functional low density area (%fLDA, voxels 
with CT attenuation above -950HU at inspiration and below -856HU at expiration). (3) %fLDA 
represents the non-emphysematous contribution to total gas trapping, namely the fraction of gas trapped 
at end expiration because of airway closure or extreme flow limitation. Moreover, Imbio LDA provides 
parametric response maps showing the regional distribution of each lung pattern. The analysis was fully 
automated and performed on an online platform called Imbio Launchpad. 
- CALIPER analysis (Figure 1E-F). Inspiratory CT scans were post-processed by using CALIPER 
(Mayo Clinic, Rochester, MN, USA), a computational platform for the near real-time characterization 
and quantification of seven lung parenchymal patterns on CT scans, including Normal, Mild Low 
Attenuation Area (LAA), Moderate LAA, Severe LAA, Ground-glass, Reticular, and Honeycombing 
(Figure 1E). (5) CALIPER is based on histogram signature mapping techniques trained through expert 
radiologist consensus assessment of pathologically confirmed datasets obtained through the Lung Tissue 
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Research Consortium (6,18). For each subject, CALIPER outputs a glyph similar to a radial space-filling 
plot providing an iconic summary of the volumetric parenchymal classification, thus facilitating the 
comprehension of the multidimensional source data. (6) The area of the glyph represents the computed 
total lung volume.  The glyph is partitioned with radial lines to illustrate the relative volumes of the left 
and right lungs and further divided into three regions, each representing the upper/middle/lower lung 
zones (Figure 1F). CALIPER analysis was fully automated and was performed onsite in the laboratory. 
7.2.3 Emphysema Severity Index (ESI) 
ESI is based on a parametric biomechanical model representing a theoretical approximation of the shape of 
the descending limb of the MEFV curve computed by assuming that at a given time the pressure lost by a fluid 
flow conveyed in a cylindrical duct is inversely related to its diameter and directly related to the fluid specific 
friction factor, density, and velocity (see the Supplemental Material for theoretical and mathematical details). 
The computation does not require standardization of input parameters, as it is directly related to the shape of 
the curve. Therefore, ESI is independent from percentage predicted values of pulmonary function variables. 
ESI value was computed in each patient using a specifically developed software application, whose theoretical 
basis is reported on the online supplement. A numerical output value ranging from 0 to 10 was used to stratify 
the dataset of 194 COPD patients according to the estimated emphysema severity.  
7.2.4 Data analysis and statistics 
By using the two thresholds of %LAA-950insp reported in literature to define absence of significant 
emphysema (6%) (7) and severe emphysema (14%) (19) we classified the patients in three subgroups: no 
emphysema (NE, %LAA-950insp <6), moderate emphysema (ME, 6≤ %LAA-950insp <14), and severe emphysema 
(SE, %LAA-950insp ≥14). 
A pairwise dissimilarity matrix was derived using SILA (Scale Indicative of Lung parenchyma 
Abnormality). SILA between a pair of CALIPER quantified CT lung volumes was computed as a cumulative 
aggregate of the differentials of normalized distributions of ordered (as mild, moderate, and severe) CALIPER 
exemplars. The unique clusters representing similar groups of patients were identified by unsupervised 
clustering of the 194x194 dissimilarity matrix using affinity propagation. The method does not require an a 
priori specification of the number of desired clusters.  
Chi-squared test was used to determine any significant differences between expected and observed 
frequencies in the clusters obtained by CALIPER and the three groups defined on the basis of %LAA-950insp 
ranges (NE, ME, SE). 
Analysis of variance, Welch’s t, and Games-Howell post-hoc tests were used to evaluate differences of the 
mean values of pulmonary function tests and ESI mean values among the three groups of emphysema severity 
defined by VIDA and Imbio LDA, as well as the clusters obtained by CALIPER.  
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To evaluate the performances of the ESI software as a classification tool we used logistic regression 
analysis. In each patient we estimated the probability of being affected by “severe” emphysema (%LAA-950insp 
≥14, data computed by VIDA) given the ESI value obtained by spirometry. In a similar manner we estimated 
the probability of “absence” of significant emphysema (%LAA-950insp <6, data computed by VIDA) given the 
ESI value.  
A ten-fold cross validation was performed over the entire dataset and we calculated the True Positives and 
False Positives rates for each fold. Sensitivity, specificity and AUC were evaluated by ROC curve analysis. In 
particular we estimated in each patient the probability of being affected by “severe” emphysema (%LAA-950insp 
>14, data provided by VIDA) given the value of ESI score obtained by spirometry;  π = Pr (Y = “Severe” | X 
= ESI) and the probability of “absence” of emphysema (%LAA-950insp <6, data provided by VIDA) given the 
value of ESI score obtained by spirometry;  π = Pr (Y = “Absence” | X = ESI). 
The software programs included Mathcad (version 2001; Mathsoft), SPSS/PC WIN 11.5.1 (SPSS, Chicago, 
IL), C++ programming language, and Orange. (20) Values of p lower than 0.05 indicated statistical 
significance. Data are expressed as mean and standard deviation (SD). 
7.3 Results 
Table 1 describes anthropometric, pulmonary function, and CT metrics data of the 194 subjects included in 
the study. Subjects were distributed across all GOLD stages: 55 stage I, 62 stage II, 56 stage III, and 21 stage 
IV.  
Figure 1 shows CT images of a patient with advanced destructive emphysema before (Fig. 1A) and after 
post-processing image analysis by using the three different software programs: VIDA (Fig. 1B), Imbio LDA 
(Fig. 1C-D), and CALIPER (Fig. 1E-F).  
Figure 2 illustrates the patients subdivision according to the pairwise dissimilarity matrix that identified 
three clusters (G1-G3), based on the SILA metric derived from the features extracted by CALIPER. Cluster 
G1 consisted of 95/194 (49%) subjects, G2 of 65/194 (33.5%) subjects, and G3 of 34/194 (17.5%) subjects. 
Across the three different clusters patients lungs were represented by a glyph, illustrating the regional 
composition of classified lung volume with color-coded sections proportional to the percentage of lung patterns 
within the region (Figure 1F). G1 was characterized by predominant Normal and Mild LAA patterns, G2 by 
predominant Moderate LAA pattern, and G3 by predominant Severe and Moderate LAA patterns. Patients 
clustered as G1 by CALIPER had either NE or ME at VIDA, whereas patients clustered as G2 had ME or SE 
and all patients clustered as G3 had SE. 
Table 2 displays the mean values of ESI and the functional data of the three groups of patients stratified by 
quantitative CT (VIDA, Imbio LDA) according to the thresholds to define different degrees of emphysema 
(NE, ME, SE) and by radiomics (CALIPER) according to the clusters of progressive emphysema severity (G1, 
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G2, G3). Patients allocation differed within the three groups defined by each of the quantitative CT post-
processing techniques. However, a significant progressive impairment from patients classified NE or G1 to 
patients classified SE and G3 was observed. Pulmonary function data were significantly different among the 
subgroups with various degrees of emphysema with a few exceptions (for further detail see the Table 1S on 
the online supplement). Lower ESI values (<5) were typical for MEFV curves obtained in COPD patients with 
NE or ME, whereas higher values (>5) were observed in patients with SE. Mean of the ESI values differed 
significantly among the three emphysema groups defined by %LAA-950insp by VIDA (p<.001) as well as among 
the three Imbio LDA groups (p<.001) and CALIPER clusters (p<.001).  
Table 3 depicts the functional differences between groups with various degrees of emphysema as classified 
by VIDA and Imbio LDA (NE, ME, SE) and by CALIPER (G1, G2, G3). 
The graph in Figure 3A represents the ten folds averaged ROC curve obtained by varying the classification 
threshold over the range of the logistic regression model output π = Pr (Y = “Severe” | X = ESI) for the 
probability of “severe” emphysema (%LAA-950insp >14, data provided by VIDA). The best results in terms of 
sensitivity and specificity were relative to the threshold value 0.47, with sensitivity=0.82 and specificity=0.87. 
The total AUC area was of 0.88. 
The graph in Figure 3B represents the ten folds averaged ROC curve obtained by varying the classification 
threshold over the range of the logistic regression model output π = Pr (Y = “Absence” | X = ESI) for the 
probability of “absence” of emphysema (%LAA-950insp <6, data provided by VIDA). The best results in terms 
of sensitivity and specificity were relative to the threshold value 0.37, with sensitivity=0.80 and 
specificity=0.85. The total AUC area was of 0.86. 
Therefore, NE is differentiated from ME/SE with a sensitivity of 0.80 and a specificity of 0.85, whereas SE 
is differentiated from ME with a sensitivity of 0.82 and a specificity of 0.87 by using the MEFV curve.  
Figure 4 shows differences in MEFV curves of two representative subjects with severe emphysema and no 
emphysema. The former has a flatter slope when flow is plotted against expired volume but not at 
pletysmographic thoracic volume, indicating greater thoracic gas compression at high-to-mid lung volumes. 
 
7.4 Discussion 
The extensive application of CT scan post-processing techniques has shown that presence and severity of 
emphysema as assessed by CT does closely reflect lung function presentation in COPD. The main finding of 
this study is that a mathematical model developed to fit the descending limb of the MEFV curve approximates 
the multimodality CT-validated emphysema stratification with an accuracy that could be suitable for clinical 
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and research purposes. The model is based only on MEFV curve morphology and, consequently, it is 
independent from percentage predicted values of pulmonary function. 
In recent years quantitative CT enabled radiologists to quantify and localize the relative volumes of 
emphysema and gas trapping in subjects with COPD by using standard CT metrics of low attenuation areas at 
pre-determined inspiratory and expiratory X-ray attenuation thresholds. (1,16) Beside CT quantification of 
emphysema, the new computational radiomics approach allows to extract multiple features from imaging data 
and to process them in order to objectively and reproducibly characterize the main pathologic changes in the 
course of lung diseases. Radiomics artificial intelligence can be used to develop non-invasive imaging 
biomarkers, which could be helpful in phenotyping heterogeneous diseases, such as COPD. (21)  
As shown in Table 2, patients allocation in an emphysema severity subgroups varies with the different CT 
metrics and radiomics approaches used. Despite this heterogeneity of classification reflecting the underlying 
methodological differences of the three CT post-processing analyses, ESI differentiates the progressive 
severity of emphysema whatever the CT method used to classify patients.  
A recent study from our group showed that a probabilistic model including DLco%, FEV1%, FEV1/VC, 
and BMI dissects with accuracy emphysematous from non-emphysematous gas trapping as assessed by 
standard CT metrics in patients with COPD. (9) Reduction in DLco is considered a marker of emphysema in 
subjects with COPD. (22) However, measurement of DLco is not widely performed and standard pulmonary 
function parameters have a wide inter-individual variability, even after normalization for ethnicity, age, and 
body size. (10) In the current study we overcame these limitations by a model depending only from MEFV 
curve morphology that does not require normalization by reference equations and, being a mathematical model 
and not a probabilistic one, it does not depend from regression coefficients reflecting the characteristics of a 
training set.  
A role for the MEFV curve in predicting the risk of emphysema was introduced as early as 1976 by 
Saltzman et al. (23) They proposed that a kinging of the descending limb of the MEFV curve might represent 
a sign of airway collapse reflecting the presence of emphysema. (23) More recently the angle between two 
regression lines fitted to the descending limb of the MEFV curve resulted to be predictive of the presence of 
emphysema on CT scan with good specificity but low sensitivity. (24) 
The kinking of MEFV curve in emphysema can be interpreted on the grounds of the wave-speed theory. 
(25) During forced expiration, alveolar pressure increases and gas is compressed within the lung, thus reducing 
lung volume and elastic recoil pressure. As a result, driving pressure and distending pressure at choke point 
decrease, thereby reducing maximal flow. As demonstrated in a recent study, this effect may be magnified in 
emphysema because of the abrupt fall of lung elastic recoil at high lung volumes and the larger amount of gas 
to be compressed. (26) The composite result of these physical phenomena is a flattening the MEFV curve. By 
contrast, the scooping of MEFV curve in COPD patients with predominant conductive airway disease may 
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reflect a smooth decrease of lung elastic recoil and a transition of the choke point towards the lung periphery 
with less gas compression. (27) Mechanisms that may contribute to the kinking of forced expiratory flow in 
emphysema are a sudden airway narrowing due to sharp decrease in lung elastic recoil and a sharp decrease of 
thoracic gas compression from mid-to-low lung volumes. (28) Therefore, flattening of the MEFV curve from 
mid-to-low lung volumes (Figure 4) could be a predictor of emphysema. At variance with the above quoted 
paper on the analysis of the MEFV curve, (24) the model presented here predicts presence and severity of 
emphysema with a considerable level of accuracy.  
This study has some limitations. First, it included a relatively small number of white Caucasian subjects 
that cannot be considered representative of the wide clinical spectrum of COPD in the general population. 
However, the distribution of CT metrics and their average values were similar to those reported from the 
COPDGene Study that included more than 10,000 subjects of two different ethnicities. (9,29) Second, the CT 
scans were acquired without spirometric control of lung inflation level during the acquisition. However, all 
subjects received prior cautious instruction on how to perform the respiratory maneuvers just before 
undergoing CT scanning by dedicated personnel. Third, radiomics is very sensitive to protocol acquisition 
parameters, algorithm definitions, and image processing. (21) Lack of standardization of these components 
severely hampers reproducibility and comparability of results. In this study all CT scans were acquired with 
the same protocol by the same personnel in each study center, and after calibration of CT scanner before each 
examination. Fourth, models based on MEFV curve strictly depend on patient effort during spirometry, as it 
affects the magnitude of thoracic gas compression. (30) This is a major determinant of the shape of the MEFV 
curve, particularly in subjects with predominant emphysema. (13) However, accurate technicians training 
could overcome this limitation. 
7.4.1 Conclusions 
This study demonstrates that the presence of emphysema and its severity in patients with COPD, as defined 
on inspiratory-expiratory CT scan by standard metrics and co-registration analysis, as well as by a 
computational unsupervised CT-based radiomics, can be accurately estimated by a mathematical model based 
on MEFV curve morphology. The model is independent from reference values and, if confirmed in larger 
populations of patients with COPD, it could be helpful in clinical practice to personalize therapy, to select 
patients for clinical and pharmacologic trials, and for the interpretation of their results whenever spirometry is 
the only available examination.  
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7.5 Tables 
Table 1. Anthropometric, pulmonary function and CT metrics data. 
N 194 
Sex (M:F) 154:40 
Age (yr) 70 (8.0) 
BMI (kg/m2) 27 (4.6) 
Smoking history (pack-years) 52 (27) 
FEV1 (% pred) 63 (26) 
FEV1/VC 48 (13) 
FEV1/FVC 52 (13) 
TLC (% pred) 108 (17) 
DLco (% pred) 69 (24) 
RV (% pred) 137 (47) 
FRC (% pred) 130 (33) 
RV/TLC 50 (14) 
 VIDA %LAA-950insp 14 (12) 
 %LAA-856exp 45 (20) 
 Imbio LDA %pLDA 12.2 (12.5) 
 %fLDA 37.1 (14.0) 
 % Normal 49.1 (21.1) 
Data are expressed as mean (SD). Legend: BMI = body mass index, DLco = lung diffusing capacity of lung for carbon 
monoxide, FEV1% = forced expiratory volume in 1 s, %fLDA = percentage of functional low density area, FRC = 
functional residual capacity, FVC = forced vital capacity, % LAA-950insp = percentage of lung attenuation area with values 
<-950 Hounsfield Units at inspiratory CT scan, %LAA-856exp = percentage of lung attenuation area with values <-856 
Hounsfield Units at expiratory CT scan, % Normal= percentage of normal lung, %pLDA= percentage of persistent low 
density area, %pred= percentage of predicted, RV = residual volume, TLC = total lung capacity, VC = vital capacity.
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Table 2. Relationship among ESI values and functional data across the groups of patients with various degrees of emphysema.  
 Emphysema severity N ESI score FEV1 % FVC % FEV1/FVC % TLC % RV % FRC % DLco % 
VIDA NE 57 1.1 (1.5) 76.1 (23.6) 93.5 (22.8) 63.1 (8.0) 100.1 (11.8) 115.0 (30.5) 109.3 (18.2) 79.7 (22.9) 
ME 58 3.1 (2.6) 63.6 (23.9) 91.4 (21.0) 54.1 (10.2) 106.9 (18.8) 134.1 (51.7) 125.3 (31.0) 75.6 (21.6) 
SE 79 6.8 (2.5) 49.9 (23.7) 91.2 (27.8) 42.4 (10.8) 115.2 (15.1) 157.6 (48.2) 147.9 (33.7) 55.9 (19.8) 
 ANOVA / Welch’s test p  <.001 <.001 .002 <.001 <.001 <.001 <.001 <.001 
Imbio LDA NE 86 1.5 (1.8) 72.6 (22.9) 92.9 (20.9) 60.5 (9.2) 101.1 (15.6) 118.2 (42.0) 111.5 (23.7) 78.9 (23.2) 
ME 46 4.6 (2.7) 63.8 (27.5) 94.1 (25.2) 52.1 (10.1) 111.9 (15.0) 145.6 (47.4) 135.4 (30.5) 72.6 (18.1) 
SE 62 7.7 (3.3) 44 (18.8) 88.6 (28.2) 39.6 (9.5) 115.7 (15.5) 160.7 (46.2) 152.1 (32.5) 51.9 (18.9) 
 ANOVA / Welch’s test p  <.001 <.001 .442 <.001 <.001 <.001 <.001 <.001 
CALIPER G1 95 1.7 (2.1) 71.9 (23.7) 92.8 (21.9) 59.8 (9.6) 101.2 (14.6) 118.7 (39.4) 113.2 (24.3) 78.4 (23.2) 
G2 65 5.4 (2.8) 59.7 (24.9) 97.1 (26.5) 48.8 (11.0) 113.4 (16.5) 145.9 (47.6) 137.9 (30.7) 65.6 (19.0) 
G3 34 8.0 (1.7) 36.8 (14.3) 79.5 (23.2) 36.5 (8.0) 118.2 (13.6) 177.3 (44.0) 163.4 (29.9) 48.1 (18.5) 
 ANOVA / Welch’s test p  <.001 <.001 .002 <.001 <.001 <.001 <.001 <.001 
Differences among groups were assessed by analysis of variance and Welch’s tests, expressed in italics and in bold if significant. Values are expressed as mean (SD). DLco %= 
percent predicted diffusing lung capacity for carbon monoxide, FEV1 %= percent predicted forced expiratory volume in 1 s, FRC% = percent predicted functional residual capacity, 
FVC% = percent predicted forced vital capacity, %LAA-950insp = percentage of lung attenuation area with values <-950 Hounsfield Units at inspiratory CT scan, ME (moderate 
emphysema, 6 ≤%LAA-950insp <14 if VIDA or 6 ≤%pLDA <14 if Imbio LDA), NE (no emphysema, %LAA-950insp <6 if VIDA or %pLDA <6 if Imbio LDA), RV% = percent predicted 
residual volume, SE (severe emphysema, %LAA-950insp ≥14 if VIDA or %LAA-950insp ≥14 if Imbio LDA), TLC% = percent predicted total lung capacity.  
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Table 3. Functional differences between groups with various degrees of emphysema. Groups are defined 
according the classification performed by VIDA and Imbio LDA (NE, ME, SE) and by CALIPER (G1, G2, 
G3). Differences were analyzed by Games-Howell post-hoc test and p values are displayed (significant p 
values are in bold). Legend: DLco %= percent predicted diffusing lung capacity for carbon monoxide, FEV1 
%= percent predicted forced expiratory volume in 1 s, FRC% = percent predicted functional residual capacity, 
FVC% = percent predicted forced vital capacity, %LAA-950insp = percentage of lung attenuation area with 
values <-950 Hounsfield Units at inspiratory CT scan, ME (moderate emphysema, 6 ≤%LAA-950insp <14 if 
VIDA or 6 ≤%pLDA <14 if Imbio LDA), NE (no emphysema, %LAA-950insp <6 if VIDA or %pLDA <6 if 
Imbio LDA), RV% = percent predicted residual volume, SE (severe emphysema, %LAA-950insp ≥14 if VIDA 
or %LAA-950insp ≥14 if Imbio LDA), TLC% = percent predicted total lung capacity.  
  FEV1% FVC% FEV1/FVC% TLC% RV% FRC% DLco% 
VIDA p NE/ME <.01 <.01 <.01 .28 <.01 <.01 <.01 
p NE/SE <.01 <.01 <.01 <.01 <.01 <.01 <.01 
p ME/SE <.01 .52 <.01 <.01 <.01 <.01 <.01 
Imbio LDA p NE/ME .16 .96 <.01 <.01 <.01 <.01 .21 
p NE/SE <.01 .56 <.01 <.01 <.01 <.01 <.01 
p ME/SE <.01 .54 <.01 .42 .23 .02 <.01 
CALIPER p G1/G2 <.01 .52 <.01 <.01 <.01 <.01 <.01 
p G2/G3 <.01 <.01 <.01 .28 <.01 <.01 <.01 
p G1/G3 <.01 <.01 <.01 <.01 <.01 <.01 <.01 
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7.7 Figures 
Figure 1. Lung parenchyma representations at CT scan after post-processing with different software 
programs in a patient with severe emphysema. A. Axial CT scan shows advanced destructive emphysema 
with a giant bulla in the right lower lobe adjacent to an area of passive atelectasis. B. Volume rendering of the 
densitometric analysis performed by VIDA shows the location and severity of emphysema at inspiratory scan 
(threshold -950HU) displaying spheres whose diameter is proportional to the relative volume of emphysema 
in each region. C-D. Coronal and Sagittal 2D images obtained by co-registration of inspiratory and expiratory 
CT scans by Imbio LDA show the location of emphysema (red), functional airways gas trapping (yellow), and 
normal lung (green). E. Volume rendering of the lung texture analysis performed by CALIPER shows the 3D 
distribution of the different lung patterns, including Normal (dark green), Mild Low Attenuation Area (LAA, 
light green), Moderate LAA (light blue), Severe LAA (dark blue), Ground-glass (yellow), Reticular (orange). 
The glyph (F) provided by CALIPER summarizes the location and amount of the different lung patterns. The 
overall area of the glyph represents the computed total lung volume, the partitions with thick radial lines 
illustrate the relative volumes of the left (L) and right (R) lungs, which are further divided with thin radial lines 
into three regions, each representing the upper (U), middle (M), lower (L) lung zones. In this patient severe 
LAA dominates in the right lower and middle lung zones, whereas middle and lower left zones are 
characterized by mild and moderate LAA.  
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Figure 2. The three clusters of COPD patients stratified represented as glyphs. Clusters (G1 to G3) 
were the result of quantitative unsupervised clustering based on a dissimilarity matrix that captures the 
distribution of classified parenchymal patterns recognized by CALIPER. G1 was characterized by predominant 
Normal (dark green) and Mild LAA (light green) patterns, whereas G2 by predominant Moderate LAA (light 
blue) pattern and G3 by predominant Severe (dark blue) and Moderate LAA (light blue) patterns. The size of 
each glyph represents patient lung volume. 
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Figure 3. ROC curve over the range of the logistic regression model output for severe emphysema 
(A) and no emphysema (B). Severe emphysema was defined at CT scan as %LAA-950insp ≥14 by VIDA 
whereas no emphysema was defined at CT scan as %LAA-950insp <6 by VIDA. The total AUC area was of 0.88 
for severe emphysema and 0.86 for no emphysema. 
  
Phenotyping COPD: correlazione clinico-radiologica dei fenotipi della BPCO 
   Page 66 
Figure 4. Maximal expiratory flow-volume curves of two representative subjects with severe 
emphysema or no emphysema. Patient with severe emphysema (left panel) had %LAA-950insp =24 whereas 
the patient with no emphysema (right panel) had %LAA-950insp=4 at CT. Note the flatter slope in the former 
when flow was plotted against expired volume (black lines) but not pletysmographic thoracic volume (grey 
lines), indicating greater thoracic gas compression at high-to-mid lung volumes.  
 
 
7.8 Supplemental Material 
7.8.1 Theoretical background and description of ESI method 
In the past many studies in human subjects have shown the presence of a functional association between the 
airflow at mouth, the instantaneous volume of the lung, and the pressure applied on the surface of the lung. 
(11,31,32) In particular the analysis of the MEFV curve has been used for many years to characterize the 
functional behavior of the bronchial tree and the surrounding parenchyma. 
In this study we tested a parametric biomechanical model representing a theoretical approximation of the 
shape of the descending limb of the MEFV curve to assess the severity of emphysema in patients with COPD 
by spirometry. The Emphsyema Severity Index (ESI) application software is based on a mathematical model 
developed to approximate the MEFV curve of each subject to ultimately provide a quantitative score ranging 
from 1 to 10. The ESI score represents a practical application of a biomechanical model developed a priori. 
No retrospective statistical inference or standardization of input parameters was required. 
The main physical principle inspiring this approach is that the pressure lost (Pl) at a given time t along an 
airway segment could be considered proportional to a specific friction factor (Ff), the air density (d) and the 
air velocity (v), similarly to the theory of the circular ducts. An inverse relationship between the pressure lost 
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and the mean diameter (D) of the airway is also supposed obtaining the following equation (better known as 
Darcy equation): 
 [1] 
By considering the hypothesis of laminar flow, the calculus of the friction factor depends uniquely on the 
Reynolds number Rn 
 [2] where  [3] 
k1 is a constant and the variable vis is the dynamic viscosity of the air fluid. 
Substituting equations [2] and [3] into equation [1] we obtain the pressure drop in the case of laminar flow 
as: 
[5] 
Considering a circular airway section we can write the air velocity in the segment as: 
 [6] 
where Φ is the resulting flow and D is the mean inner diameter of the airway segment. Substituting equation 
[6] into [5] we obtain the association between the airflow and the pressure lost, as of laminar flow hypothesis. 
 [7] 
Equation [7] shows that the relationship between the pressure lost and the airflow seems to be linear in 
laminar flow approximation. 
 
In the past some authors proposed lumped parametric models to fit the MEFV curve acquired during 
maximal effort test, taking into account linear association profiles between airways resistance and airflow. The 
studies obtained acceptable waveforms and good fitting of the curve. (32) 
Pl= Ff ⋅ d⋅ v
2
2⋅ D
Ff = k1Rn Rn=
v⋅ D
vis
Pl= k1/2⋅ vis⋅ d⋅ v
D2
v= 4⋅Φ
D2⋅π
Pl= k2⋅ vis⋅ d⋅Φ
D4
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At variance with past models, we proposed a mathematical model for the approximation of the MEFV curve 
developed under the hypothesis that the airflow measured at the mouth through standard spirometry could not 
be considered as a laminar flow. As a consequence the Ff variable could not be calculated as a scaled inverse 
of the Reynolds number Rn (laminar flow), but a more complex calculation is required to estimate the pressure 
drop. Colebrook proposed the following equation for the calculation of the friction factor, where Ru is the 
mean relative roughness of the airway segment (4): 
 [8] 
Although the Colebrook’s equation is usually solved numerically due to its implicit nature, simplified 
versions have been proposed in the past (i.e. the Altshul-Tsal (33) formulation to estimate an approximated Ff 
factor). Nonetheless, despite of the analytical procedure for the estimation of Ff, the final equation that 
describes the pressure drop is the following: 
 [9] 
where K3 and Ff are constant values for a specific patient and airway segment, d is the air density, Φ is the 
resulting flow and D is the mean inner diameter. 
One interesting observation deriving from these mathematical models is that the pressure drop Pl along a 
segment is inversely proportional to the diameter of the airway power 4 or 5. It follows that a minimal variation 
in airway diameter is amplified to cause a significant pressure drop along the whole segment. This shows how 
the regulation of the respiratory airways walls efficiently modulates the airflow. 
Another important characteristic of the non-laminar flow hypothesis is the quadratic association between 
the airflow and the pressure lost along the airways, while this relationship would be linear if the measured flow 
at the mouth was hypothesized as laminar.  
As a consequence the lumped parametric model of a maximal flow volume curve implemented in the ESI 
model is based on the following non-linear equation: 
 [10] 
1
Ff 0.5
=− 2⋅ log10 ( Ru
3.7⋅ D +
2,51
Rn⋅ Ff 0.5
)
Pl= K3⋅ Ff ⋅ d⋅Φ
2
D5
Φ(V )= 1− a1⋅ V
2
a2+ a3⋅ V 2
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where the numerator represents a simple model of the quadratic pressure profile during a maximal function 
test and the denominator represents the model of the exhaled volume-dependent quadratic airways resistance 
profiles. The best a1, a2 and a3 coefficients are estimated iteratively by the software, which performs a Least 
Mean Squares fitting of the descending limb of the MEFV curve. 
Once the best mathematical model fitting the raw data is obtained, the software then proceeds to the calculus 
of the first and second derivatives for the specific fitted MEFV curve. This procedure is performed to search 
the inflection point Vf of the descending limb of the MEFV curve.  
 [11] 
The point Vf is very important in assessing emphysema severity, as its abscissa represents the lung volume 
(in liters) at which the resistance profile becomes influenced by the lost in elastic recoil due to the parenchymal 
destruction. This creates an inversion in the concavity of the descending limb of the MEFV curve.  
This type of analysis was not possible before because of the hypothesis of the above-mentioned linear 
models. Indeed, in those models the second derivatives profiles did not admit acceptable solutions to the 
equation [11]. 
After the solutions of equation [11] are calculated, the first derivative is then evaluated in correspondence 
of the acceptable solution (volume value) Vf and re-mapped between 0-10 over the angle range (20° - 80°) 
generating the quantitative index called ESI. The computation does not require standardization of input 
parameters, as it is directly related to the shape of the curve. Therefore, ESI is independent from percentage 
predicted values of pulmonary function variables. ESI value was computed in each patient using a specifically 
developed software application, based on the above theoretical basis. A numerical output value ranging from 
0 to 10 was used to stratify the dataset of 194 COPD patients according to the estimated emphysema severity.  
 
The Figure 1S shows a box-plot representing the %LAA-950insp distribution (I-III quartiles) in the validation 
dataset in three subgroups: no emphysema (NE, %LAA-950insp <6), moderate emphysema (ME, 6≤ %LAA-950insp 
<14), and severe emphysema (SE, %LAA-950insp ≥14). The intersection of the ESI values (red line) with the 
corresponding box indicates the most probable severity class for the case analyzed. In this example the case 
analyzed had a low probability of having SE. 
∂ ' 'Φ(V )
∂V
= 0
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7.8.2 Post-processing imaging techniques 
Figure 2S show images obtained by using VIDA software program in two COPD patients. Panel A shows 
the results obtained in a patient with advanced destructive emphysema whereas panel B shows the results 
obtained in a patient with small airway disease. In panel A the parenchymal destruction at axial CT scan 
correlates with the big bullae of %LAA-950insp detected by VIDA analysis. Vessels are lacking in 
emphysematous areas. In panel B the thickening of airway walls and the tiny bilateral ground-glass 
micronodules on axial CT scan are consistent with small airway disease. Although no significant areas of 
emphysema were found by VIDA analysis, the gas trapping at end-expiration due to airway disease was 
evident. 
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Figure 3S shows coronal and sagittal pulmonary parametric response maps obtained by using Imbio LDA 
analysis in a subject with emphysema predominantly located in lower lobes. The parametric response maps 
identify and localize the three color-coded density patterns at co-registration analysis: normal lung in green 
(percentage of voxels with CT attenuation greater than -950 HU at inspiration and greater than -856 HU at 
expiration), persistent low density area in red (%pLDA, voxels with CT attenuation below -950HU at 
inspiration and below -856HU at expiration), and functional low density area in yellow (%fLDA, voxels with 
CT attenuation above -950HU at inspiration and below -856HU at expiration). 
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Figure 4S shows the permuted dissimilarity matrix illustrating the abnormality based pairwise 
dissimilarities (brighter the shade higher the dissimilarity) among the features extracted by CALIPER and 
obtained with SILA. The nine blocks represent the first-pass clusters and the three diagonal blocks represent 
the final three unique stratified clusters (G1, G2, G3). 
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The value of maximal expiratory flow-volume curve in estimating the presence and 
severity of emphysema as assessed on CT 
Mariaelena Occhipinti, Matteo Paoletti, Elizabeth Regan, David A. Lynch, James D. Crapo, Stefano 
Colagrande, Edwin K. Silverman, Massimo Pistolesi and the COPDGene investigators 
(Accepted for Presentation at American Thoracic Society Conference, Dallas, 17-18/05/2019) 
 
Chapter 8 - Validation ESI model 
In the previous chapter we have proposed a mathematical model (ESI method) to predict the presence of 
emphysema as assessed at CT by using functional parameters derived from MEFV curve. The model was built 
using the Italian cohort of CLIP-COPD Study. To validate our model we tested it in the largest population of 
COPD patients available worldwide: the COPDGene Study population. Despite our cohort, this population 
included thousands of subjects and different ethnicities. 
  
 
 
 
 
 
Rationale: To assess whether a mathematical model derived from the maximal expiratory flow-volume 
(MEFV) curve could predict with accuracy the severity of emphysema as defined by parameters derived from 
quantitative computed tomography (CT). To validate the model in a large population of subjects with chronic 
obstructive pulmonary disease (COPD).  
Methods: CT metrics of emphysema were assessed on the inspiratory CT scans of 194 white COPD patients 
who underwent pulmonary function testing. Three groups of emphysema severity were identified according to 
CT metrics of emphysema (low attenuation area below -950HU at inspiration, %LAA-950insp): no emphysema 
(%LAA-950insp<6%), mild-moderate emphysema (6%<%LAA-950insp<14%), and severe emphysema (%LAA-
950insp>14%).  
An index to estimate emphysema severity (ESI) as assessed by CT was developed by using a parametric 
mathematical model fitting the descending portion of MEFV curve. A numerical output value ranging from 0 
to 10 was used to stratify the dataset according to the estimated emphysema severity. Model outputs were then 
compared to CT metrics to evaluate the performances of ESI model. Validation of the model was performed 
on 4000 COPDGene subjects, including whites and African Americans.  
Analysis of variance, Welch t, and Games-Howell post-hoc tests were used to evaluate differences between 
the three groups of emphysema defined by CT metrics. ROC curve (AUC) analysis was used to calculate the 
accuracy of the model by varying the threshold over the range of the ESI score. 
 
Results: Subjects were distributed across GOLD stages I to IV and evenly distributed across the three 
groups of emphysema severity (59 with no emphysema, 58 with moderate emphysema, 77 with severe 
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emphysema). Mean of the ESI score differed significantly among the three emphysema severity groups 
(p<.001) in both the first cohort and the COPDGene population, with lower scores (<5) in subjects with severe 
emphysema and higher scores (>5) in patients with no or mild emphysema. The model had an overall 85% 
accuracy (87% sensitivity and 83% specificity) in the first cohort and 82.5% accuracy (82% sensitivity and 
83% specificity) in the COPDGene population.  
Conclusions: Milder and severe emphysema as assessed by quantitative CT can be accurately estimated 
by a mathematical model based on the MEFV curve. The model was created uniquely on unstandardized 
functional data derived from the MEFV curve, avoiding the use of percent-predicted values, anthropometric 
and ethnicity parameters. These characteristics make this approach convenient for clinical trials as well as for 
clinical routine. 
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Chapter 9 - Which criteria to define COPD? 
In the previous chapters we have shown that statistical models including either BMI and functional data or 
parameters of the flow-volume curve can estimate with a considerable accuracy the emphysema extent as 
assessed on quantitative CT in a population of subjects diagnosed with COPD. However, the criteria to define 
expiatory airflow obstruction are still matter of international debate (1)(2).  
We aimed at investigating the functional and radiological presentation of those subjects defined as COPD 
by Global Initiative for Chronic Obstructive Lung Disease (GOLD) criterion (FEV1/FVC<0.70) but excluded 
by European Respiratory Society/American Thoracic Society criterion (FEV1/FVC<LLN). 
 
Unmasking COPD in patients excluded by the lower limit of normality 
Mariaelena Occhipinti, M Paoletti, C Nardi, M Palazzi, G Camiciottoli, R inchingolo, S Colagrande, AR 
Larici, M Pistolesi 
 (Oral presentation at the ESTI Congress - European Society Thoracic Imaging, Geneva, 24-26/05/2018) 
 
9.1 Background 
Airflow limitation has been defined by the GOLD when the post-bronchodilator fixed ratio of FEV1 to FVC 
is less than 0.7, regardless of age and sex of the patient (3). Despite of the its simplicity of use in daily clinical 
practice (4), the fixed ratio does not take into account the normal age-dependent decline in lung function, with 
a consequent overdiagnosis of chronic obstructive pulmonary disease (COPD) in older people and 
underdiagnosis in younger people (5, 6). At 80 years of age 20–25% of the reference population would have 
low values compatible with pathological airflow limitation instead of the expected 5%, with a consequent high 
rate (75–80%) of false positive results (5).  
Due to the general aging of the population, age differences are going to play an important role in the 
definition of disease in next future. To overcome the issue of overdiagnosis in the elderly, the European 
Respiratory Society/American Thoracic Society task force recommended to use a criterion based on the lower 
limit of normal (LLN) values, appropriate for age, sex, and ethnicity of the individual to define obstruction at 
spirometry (1, 2, 7). Equations to predict the correct reference values for spirometry in each individual were 
derived from about 80,000 subjects of both sexes and many ethnicities, across all ages (3 to 95 years) (8). 
According to the LLN criterion, patients diagnosed with COPD by GOLD criteria may be excluded and 
considered as non-obstructed.  
As the population gets older, recognition of the imaging features of “normal” aging is likely to become 
increasingly important to differentiate from clinically significant disease (9). The lungs age and it has been 
suggested that COPD is a condition of accelerated lung aging (10). The distinction between normal aging lung 
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and COPD is a big challenge and of great interest nowadays. Post-processing imaging tools enable the 
quantification of parenchymal destruction as well as small airway disease. However, qualitative analysis of 
chest CT images provides invaluable data on the presence not only of COPD signs but also of 
paraphysiological abnormalities due to aging. 
We aimed at investigating the presence of imaging findings indicative for COPD with both quantitative and 
qualitative analyses of CT scans in those subjects excluded by LLN criteria, a group older than those included 
by LLN criteria. Furthermore, we used qualitative analysis to define the COPD subtypes in this subset of 
population and to assess the concordance between readers. Finally, we evaluated the accuracy of our predictive 
statistical models in estimating the risk of having emphysema at CT in the group of subjects included by GOLD 
and in those included by ERS criteria. 
9.2 Methods 
This was a two-center study approved by the institutional Ethics Committees of the University of Florence 
and the Catholic University of Sacred Heart in Rome. The study was based on a retrospective interpretation of 
prospectively acquired data. From January 2012 to December 2016, subjects with diagnosis of COPD 
(FEV1/VC<0.70) (2, 7, 11) were considered for inclusion if they satisfied the following inclusion criteria: age 
40-85 years, smoking history >10 pack-years, no COPD exacerbations within one month, no diagnosis of 
asthma or cardiac disease, and acceptance to participate by written informed consent. Sixteen out of 232 
eligible subjects were excluded because of incomplete data. Part of the 216 subjects enrolled participated in 
previous studies (12-14).  
9.2.1 Functional evaluation 
Subjects underwent complete pulmonary function tests by using a mass-flow sensor and multigas analyser 
(V6200 Autobox Body Plethysmograph Sensor Medics, Yorba Linda, USA, or Platinum Elite™ Body 
Plethysmograph, Medical Graphics Corporation, St. Paul, MN, USA), arterial blood gases by Radiometer 
ABL90 FLEX or ABL800 FLEX (Brønshøj, Denmark). Pre- and post-bronchodilator spirometry, lung 
volumes, and single-breath DLco were obtained according to standard ATS/ERS (American Thoracic 
Society/European Respiratory Society) recommendations (15-17). All subjects had FEV1/FVC<0.70 and 157 
also below the lower limit of normality (LLN) criterion, defined as the 5th percentile of the reference population 
(Table 1) (2, 7, 11). LLN individual values were obtained by using the online calculator 
(http://gligastransfer.org.au/calcs/spiro.html) by the Global Lung Function Initiative of the ERS. The 
automated calculator uses prediction equations derived from about 80,000 subjects of both sexes and many 
ethnicities (8).  
9.2.2 CT scanning technique and analysis 
In each center volumetric chest CT scans were obtained by the same team and the same CT scanner 
(SOMATOM Sensation 64, Siemens, Erlangen, Germany, or SOMATOM Definition FLASH 128, Siemens, 
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Erlangen, Germany) within 48 hours of the functional evaluation. CT scans were acquired at full inspiration 
and forced end-expiration using the acquisition protocol adopted in the COPDGene Study (18) with the 
following parameters: 120 kVp, 200 mAs, rotation time 0.5 sec, slice thickness 0.6 mm, pitch 1.1 and 
reconstructions kernels b31f (smooth) and b70f (sharp). Subjects were instructed on how to perform respiratory 
maneuvers while lying supine in the CT scanner with arms fully abducted. No contrast medium was injected.  
Quantitative analysis was performed on images with reconstruction kernel b31f by using two different 
software programs (VIDA and Imbio LDA). VIDA software provided relative volumes of lung attenuation 
areas with values below -950 HU at inspiration (%LAA-950insp) and below -856 HU at expiration (%LAA-856exp) 
to quantify emphysema and total gas trapping, respectively. Imbio LDA provided relative volumes of 
functional low density area (%fLDA), persistent low density area (%pLDA), and normal lung (%Normal).  
Qualitative analysis was performed according to the Fleischner Statement criteria to define COPD subtypes, 
including advanced destructive emphysema (ADE), confluent centrilobular emphysema, moderate 
centrilobular emphysema, mild centrilobular emphysema, trace centrilobular emphysema, panlobular 
emphysema, mild paraseptal emphysema, substantial paraseptal emphysema, and airway-predominant disease 
(19). Two radiologists (one dedicated thoracic radiologist and one general radiologist) evaluated all CT scans 
first separately and then after 4 months in consensus. 
9.2.3 Statistical model application 
The binary logistic regression models presented in Chapter 3 (BMI, FEV1%, FEV1/VC, DLco%) and 
Chapter 5 (BMI, FEV1/FVC, slope of the flow-volume curve between 25% and 50% of FVC) were applied to 
the whole group of subjects (FEV1/FVC <0.7) as well as in the subgroup with FEV1/FVC <LLN. 
9.2.4 Data analysis and statistics 
Welch's t-test was used to evaluate differences in functional, anthropometric, and CT metrics data among 
groups included and excluded by LLN criterion. 
Agreement between the two readers was tested by using k-Cohen coefficient.  
ROC curve (AUC) analysis was used to calculate the accuracy of the models considering a logistic 
probability threshold (pth) at value of 0.5. 
The software programs included Mathcad (version 2001; Mathsoft), SPSS/PC WIN 11.5.1 (SPSS, Chicago, 
IL), and C++ programming language. Values of p lower than 0.05 indicated statistical significance. Data are 
expressed as mean and standard deviation (SD). 
9.3 Results 
The use of the LLN to our population excluded 46/216 (21.3%) patients. The anthropometric, functional, 
and imaging characteristics of the group excluded by LLN criteria is detailed in Table 1. Sex, age, BMI, and 
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smoking history were not statistically different between the group included and the group excluded by LLN 
criteria. The group excluded by LLN criteria had a significantly higher FEV1/FVC, FEV1/VC, DLco% and 
lower TLC, RV, FRC, RV/TLC. Emphysema and gas trapping were significantly lower in the group excluded 
by LLN criteria, with average values of normality (19, 20). 
Patients complained of cough (28/46, 61%), sputum (18/46, 39%), and wheezing (1/46, 2%), with an 
average modified Medical Research Council questionnaire of 2. Smoking history was similar to those defined 
COPD by using the GOLD criteria. 
At quantitative CT analysis the group excluded by LLN differed significantly from those included as of 
amount of emphysema (%LAA-950insp and %pLDA), total gas trapping (%LAA-856exp), and functional gas 
trapping (%fLDA) (Table 1). 
At qualitative CT analysis consensus reading identified signs of COPD in all 46 subjects excluded by LLN 
criteria. In particular, 3 subjects presented with airway disease, 16 with paraseptal emphysema, and 27 with 
centrilobular emphysema (Table 2). Nineteen out of 46 cases (41%) were moderate-to-severe emphysema 
subtypes, by grouping those with any kind of moderate-to-severe emphysema (substantial paraseptal 
emphysema, advanced destructive emphysema, confluent centrilobular emphysema, and moderate 
centrilobular emphysema). Sixteen out of 46 cases (35%) excluded by LLN criterion had paraseptal 
emphysema, which is a higher rate than in the general COPD population reported in literature. 
Concordance between the readers was good (k= 0.61) (Figure 1). This result suggests that a dedicated 
training is not mandatory to classify COPD subtypes. The biggest difference was noted between airway disease 
and mild centrilobular emphysema, as the cases defined as airway disease by the thoracic radiologist were 
classified as either mild or trace centrilobular emphysema by the general radologist (Figure 2). 
The binary logistic regression model including the slope of the flow-volume curve between 25% and 50% 
of FVC (S25-50), BMI, and FEV1/FVC predicted the probability of having emphysema with 85% accuracy (87% 
sensitivity and 81% specificity) in the whole group of subjects (GOLD criterion) and 82% accuracy (82% 
sensitivity and 83% specificity) in the subgroup with FEV1/FVC<LLN (ERS/ATS criterion) (Figure 3). The 
probabilistic model including BMI, FEV1%, FEV1/FVC, and DLco% predicted the probability of having 
emphysema with 80% accuracy in the whole group of subjects (GOLD criterion) and 77% accuracy in the 
subgroup with FEV1/FVC<LLN (ERS/ATS criterion) (Figure 3). 
9.4 Tables 
Table 1. Anthropometric, pulmonary function, and CT metrics data of: A) GOLD dataset (patients with 
COPD enrolled according to GOLD criterion of the fixed ratio of FEV1/FVC <0.70); B) LLN dataset (patients 
with COPD enrolled according to LLN criterion); C) patients excluded by LLN criterion. Data are reported as 
mean (SD). Welch's t robust test was used to test the hypothesis that the two B-C subgroups had equal means. 
Smoking history is expressed as pack-years.  
Phenotyping COPD: correlazione clinico-radiologica dei fenotipi della BPCO 
   Page 80 
 A) GOLD dataset B) LLN dataset C) Patients excluded by LLN criteria 
Welch's t test 
(B vs C) 
N 216 170 46  
Sex (M:F) 169:47 131:39 39:7 - 
Age (years) 70.2 (8.0) 69.9 (8.3) 71.2 (7.2) ns 
BMI (kg/m2) 26.5 (4.6) 26.3 (4.5) 27.5 (4.84) ns 
Smoking history 51.7 (27.0) 50.8 (23.9) 55.1 (37.3) ns 
FEV1% 62.6 (25.8) 56.0 (22.6) 90.0 (21.0) p<.01 
FEV1/VC (%) 47.5 (13.2) 43.9 (11.6) 62.8 (7.2) p<.01 
FEV1/FVC (%) 52.3 (13.1) 48.6 (11.5) 67.6 (7.1) p<.01 
TLC% 108.2 (16.5) 110.7 (16.6) 97.6 (11.3) p<.01 
DLco% 68.9 (23.5) 64.3 (22.1) 86.6 (22.3) p<.01 
RV% 137.0 (46.7) 146.3 (45.5) 97.7 (26.8) p<.01 
FRC% 129.5 (32.6) 135.7 (32.0) 103.9 (19.6) p<.01 
RV/TLC (%) 49.9 (14.1) 52.6 (13.9) 38.7 (8.2) p<.01 
%LAA-950insp 14.3 (11.7) 16.3 (12.0) 6.1 (5.2) p<.01 
%LAA-856exp 45.2 (20.3) 49.2 (19.0) 28.4 (16.7) p<.01 
%fLDA 36.9 (13.7) 38.8 (12.8) 28.3 (14.5) p<.01 
%pLDA 12 (11.7) 16.3 (12.0) 7.5 (5.2) p<.01 
Legend: BMI = body mass index, DLco% = percentage of predicted diffusing capacity of lung for carbon monoxide, 
FEV1% = percentage predicted of forced expiratory volume in 1 second, %fLDA = percentage of functional low density 
area, FRC% = percentage of predicted functional residual capacity, FVC% = percentage of predicted forced vital capacity, 
%LAA-950insp = percentage of lung attenuation area with values below -950 Hounsfield Units at inspiratory CT scan, 
%LAA-856exp = percentage of lung attenuation area with values below -856 Hounsfield Units at expiratory CT scan, 
%pLDA = percentage of persistent low density area, RV% = percentage of predicted residual volume, TLC% = percentage 
of predicted total lung capacity, VC = vital capacity. 
 
Table 2. Qualitative analysis of chest CT scans. Distribution of COPD subtypes in subjects with FEV1/FVC 
>LLN. Data represent case numbers. 
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9.5 Figures 
Figure 1. Distribution of COPD subtypes at qualitative CT analysis performed by a dedicated thoracic 
radiologist and a general radiologist in 46 subjects excluded by LLN criterion. Differences in classification 
were greater in airway disease and mild centrilobular emphysema. 
 
Legend: AD=airway disease, ADE= advanced destructive emphysema, CLE= centrilobular emphysema, PSE= paraseptal 
emphysema. 
 
Figure 2. Similarities and dissimilarities in classification of COPD subtypes at qualitative CT analysis 
performed by a dedicated thoracic radiologist and a general radiologist in 46 subjects excluded by LLN 
criterion. 
Centrilobular emphysema (27) Paraseptal emphysema 
(16) 
Airway 
disease 
ADE Confluent Moderate Mild Trace Panlobular Substantial Mild  
2 4 6 6 9 0 7 9 3 
Phenotyping COPD: correlazione clinico-radiologica dei fenotipi della BPCO 
   Page 82 
 
Legend: AD=airway disease, ADE= advanced destructive emphysema, CLE= centrilobular emphysema, PSE= paraseptal 
emphysema. 
 
 
Figure 3. ROC curves of the two logistic models. The black curves represent the MEFV curve-based model 
for subjects with FEV1/FVC<0.70 (left panel) and for subjects with with FEV1/FVC<LLN (right panel). The 
grey curves represent the DLco-based model for subjects with FEV1/FVC<0.70 (left panel) and for subjects 
with with FEV1/FVC<LLN (right panel). Grey curves data are derived from reference (21). 
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Chapter 10 - Future directions 
The evolution of knowledge concerning COPD covers 200 years (1). Although recently the interest towards 
COPD has increased and research in the field is growing fast, there are still many questions to answer.  
Our next studies will focus on the longitudinal evaluation of patients with COPD in order to investigate the 
natural history of this disease by using on one hand cutting-edge radiological methodologies and on the other 
hand a close clinical approach. The collaboration with researchers with great expertise in the field (the 
COPDGene Study research group) will be the key to answer interesting questions of basic research that may 
rapidly translate into key points for patient treatment.  
A few physicists around the world are developing post-processing imaging techniques to assess pulmonary 
vessels without the need of contrast media injection (2). The application of these tools may contribute to an 
accurate characterization of the different endotypes. Many years ago post-mortem studies have already shown 
significant differences in lung vascularization between patients with emphysema and those with small airway 
disease (3, 4). However, the in vivo characterization of lung vessels could help in the management of those 
patients that are prone to develop pulmonary hypertension. 
The use of innovative radiological tools will be combined with an accurate qualitative assessment of chest 
CT scans, according to the Fleishner Society Statement (5). The evaluation will not be limited to the definition 
of CT-subtypes, but it will take into account associated features of COPD, such as tracheobronchomalacia, 
bronchiectases, coexistence of interstitial lung disease, pulmonary hypertension, morphology of chest wall and 
large airways. 
Further development of the online App based on the ESI model described in Chapter 6 is ongoing to 
eventually help pulmonologists and primary care physicians in defining COPD endotypes tomorrow and in 
targeting therapy accordingly.  
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Chapter 11 - Conclusions 
This thesis describes the use and development of innovative tools, both radiological and bioengineering, in 
supporting clinical diagnosis and phenotypization of chronic obstructive pulmonary disease (COPD). 
Radiology was coupled with pulmonary function to better understand this complex and heterogeneous disease 
and to describe its phenotypes and endotypes.  
An overview of the clinical complexity and heterogeneity of COPD and the current role of imaging is 
presented in chapter 1. Chapter 2 explains the current role of qualitative and quantitative imaging, recent 
advances in post-processing image analysis and imaging tools dedicated to research in this field.  
The studies described from chapter 3 to chapter 7 are the core of the thesis, consisting of the models 
developed from clinical and functional data to evaluate the presence of emphysema in patients with expiratory 
airflow obstruction. Imaging tools are used to assess CT endotypes and as referring gold standard for the 
models. In chapter 3 we demonstrated that standard imaging metrics obtained by inspiratory and expiratory 
CT scans can be used to identify and quantify the relative contribution of emphysematous and non-
emphysematous gas trapping, allowing a better definition of COPD patient subtypes. The definition of the 
prevalent CT subtype (i.e. emphysema versus airway disease) of COPD could potentially be used to target 
patient therapy to the underlying COPD endotype. Moreover, a logistic model combining BMI, DLco%, 
FEV1%, and FEV1/VC proved to be accurate in predicting CT-based quantification of emphysema grade, 
which may prove useful when assessing COPD patients who do not undergo chest CT.  
In chapter 4 and 5 we further explored the chances to use functional parameters to estimate the presence of 
emphysema at CT by using statistical models. In chapter 4 we tried to exclude DLco and to use only functional 
parameters directly derived from the spirometric flow-volume curve without standardization for sex, age, and 
ethnicity data. In chapter 5 we took into account the shape of the flow-volume curve itself. The level of 
accuracy of both models was high and suitable for clinical practice as well as for pharmacologic trials. 
The deep thoughts on the flow-volume curve inspired us to develop a mathematical model (ESI) entirely 
based on the curve, as described in chapter 6. This model classifies patients with milder or more severe 
emphysema, as defined by quantitative CT metrics, without the need of anthropometric or standardized 
parameters. Moreover, in this chapter lung texture analysis was used to study the presentation of lung patterns 
in COPD patients. An unsupervised radiomics approach identified three clusters of patients and their 
presentation at pulmonary function tests was described. The ESI model created from a cohort of Caucasians 
was then validated in the largest population of COPD patients ever studied (the COPDGene Study) including 
different ethnicities (chapter 7). The application of the ESI model to such a big and heterogeneous population 
supported the results obtained in our small cohort. This result put the foundations for using ESI model in 
randomized controlled trials to test treatment efficacy according to COPD endotypes and not only to the 
simplistic approach of FEV1 reduction and exacerbation rate that overlook the physio-pathogenetic 
mechanisms underlying airflow obstruction. 
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In chapter 8 and chapter 9 we examined the ongoing questions and future directions of research in the field. 
In particular, in chapter 7 we wonder about the criteria to define COPD, as the adoption of the LLN criterion 
excluded subjects with relevant COPD findings at CT scan. Moreover, we explored the concordance between 
a dedicated thoracic radiologist and a general radiologist to define COPD CT-subtypes. In chapter 8 I discussed 
the future research directions towards the need for longitudinal studies, assessment of lung vessels, qualitative 
assessment of COPD subtypes, and development of a handy App for clinicians to define the presence of 
emphysema without undergoing chest CT scan. 
All the work presented is the result of a strict and passionate collaboration of experts in different fields: 
pulmonologists, radiologists, and bioengineers. This collaboration is challenging, intriguing, stimulating, and 
fundamental for making advances in research when the topic is as complex and heterogeneous as COPD.
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